

1. Capretti L., Bonora E., Coscelli C., Butturini U. Combined sulphonylurea-biguanide therapy for NIDDM. Metabolic effects of glibenclamide and metformin or phenformin in newly diagnosed obese patients. *Curr. Med. Res. Opinion* 7: 677-683, 1982.
2. Fallucca F, Barbetti F, Maldonato A, Spallone V, Giangrande L, Gambardella S. Effects of somatostatin on established induced ketosis. *Horm Metabol Research* 14: 512-515, 1982.
3. Vigneri R, Pezzino V, Wong KY, Goldfine ID. Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to its receptors in target cells. *J Clin Endocrinol Metab.* 54:95-100, 1982.
4. Pezzino V, Trischitta V, Purrello F, Vigneri R. Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells. *Diabetologia* 23:131-135, 1982.
5. Trischitta V, Gullo D, Pezzino V, Vigneri R. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients. *J Clin Endocrinol Metab.* 57:713-718, 1983.
6. Goldfine ID, Iwamoto Y, Pezzino V, Trischitta V, Purrello F, Vigneri R. Effects of biguanides and sulfonylureas on insulin receptors in cultured cells. *Diabetes Care* 7 (Suppl 1):54-58., 1984.
7. Vigneri R, Gullo D, Pezzino V. Metformin and insulin receptors. *Diabetes Care* 7 (Suppl 1):113-117, 1984.
8. Bonora E., Cigolini M., Bosello O., Zancanaro C., Capretti L., Zavaroni I., Coscelli C., Butturini U. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in nondiabetic subjects. *Curr. Med. Res. Opinion* 9: 47-51, 1984.
9. Coscelli C., Palmari V., Saccardi F., Alpi O., Bonora E. Evidence that metformin addition to insulin induces an amelioration of glycemic profile in type I (insulin-dependent) diabetes mellitus. *Curr. Therap. Res.* 35: 1058-1064, 1984.
10. Sinagra D Optimum therapy of insulin-dependent diabetes mellitus. *Recenti Prog Med.* Sep;75(9):823-32, 1984.
11. Ferrara L, Capaldo B, Rivellese AA, Genovese S, Iovine C, Russo L, Mancini M. Effects of β -receptor blockade on carbohydrate metabolism. *JOURNAL OF HYPERTENSION*, vol. 3 (suppl. 3), p. 199-201, 1985.
12. Parillo M., Giacco R., Riccardi G., Pacioni D., Rivellesi A Different glycaemic responses to pasta, bread, and potatoes in diabetic patients *Diabetic Medicine* 2:374, 1985.
13. Rivellese A., Parillo M., Iovine C., Giacco A., De Marco F, Perrotti N., Riccardi G.,

- Mancini M. A fibre rich diet for the treatment of diabetic patients with chronic renal failure. *Diabetes Care* 8, 1985.
14. Pozzilli P, Ghirlanda G, Manna R, Alfano G, Greco AV, Andreani D. White cells transfusion in recent onset type 1 diabetes. *Diabetes Res.* 3(5):273-6, 1986.
 15. . Ferrara L, Capaldo B, Rivellese A, Genovese S, Iovine C, Mastranzo P, Cirillo F, Mancini M. Adrenergic system and carbohydrate metabolism. Effects of beta receptor blockade on insulin secretion and peripheral insulin sensitivity in normoglycemic patients. *EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY*, vol. 33, p. 273-277, 1987.
 16. Bonora E., Pisani F., Micciolo R., Corgnati A., Muggeo M. Effect of glipizide on insulin secretion and insulin metabolism in obese type 2 diabetic patients. *Diabetes Care* 10: 687-691, 1987.
 17. Pozzilli P, Visalli N, Cavallo MG, Beales P, Negri M, Ghirlanda G, Papa V, Andreani D. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin. *Diabetes Res.* Oct;6(2):51-6, 1987.
 18. Maldonato A, Iavicoli M, Fallucca F. When to start a NIDDM patient on insulin: which insulin programme could be recommended? *Diabetes Res Clin Pract* 4: 29-34, 1988.
 19. Purrello F, Gullo D, Buscema M, Pezzino V, Vigneri R, Goldfine ID. Metformin enhances certain insulin actions in cultured rat hepatoma cells. *Diabetologia*; 31:385-389, 1988.
 20. Cignarelli M, Cospite MR, Rosco M, Garruti G, De Pergola G, Giorgino R. Responses to chickling vetch and bread meals in normal and type 2 non-insulin-dependent diabetic subjects. *Diab. Med.* 5: 501-502, 1988.
 21. Cignarelli M, De Pergola G, Paternostro A, Garruti G, Cospite MR, Nardelli GM, Giorgino R. Plasma glucose, free fatty acids and insulin response to single and mixed chickling vetch (*lathyrus sativus*) meal in type 2 non-insulin-dependent diabetic subjects. *Diab. Nutr. Metab.*; 1: 187-191, 1988.
 22. Pezzarossa A., Taddei F., Cimicchi M.C., Rossini E., Contini S., Bonora E., Gnudi A., Uggeri E. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. *Diabetes Care* 11: 52-58, 1988.
 23. Pozzilli P. Immunotherapy in type 1 diabetes. *Diabet Med.* 5(8):734-8, 1988.
 24. Bonora E., Muggeo M. Further considerations regarding insulin secretion and metabolism after glipizide treatment. *Diabetes Care* 11: 690-692, 1988.
 25. Parillo M., Pacioni D., Iovine C, Contaldo F., Isernia C, Demarco F., Perrotti N., Rivellese A. Metabolic effects of a high CHO-high fibre diet for the treatment of diabetic patients with

- chronic kidney failure. *Am J Clin Nutr* 48:255-9, 1988.
26. Parillo M., Coulston A., Hollenbeck C., Reaven G: Effect of a low fat diet on carbohydrate metabolism in patients with hypertension. *Hypertension*, 244-248, 1988.
 27. Parillo M, Giacco R, Rivellese A, Giacco A, Iovine C, Riccardi G. Acute effects on pancreatic hormones and blood lipids of bread and spaghetti consumed within a meal. *Diab Nutr Metab* 1:133, 1988.
 28. Perriello G, Torlone E, Di Santo S, Fanelli C, De Feo P, Santeusano F, Brunetti P, Bolli GB. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*. 31(11):811-5, 1988.
 29. Sinagra D, Randazzo C. Alternative systems of insulin administration. *G Clin Med*. 70(8-9):529-34, 1989.
 30. Trischitta V, Italia S, Borzì V, Tribolato A, Mazzarino S, Squatrito S, Vigneri R. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide. *Diabetes Care*; 12: 582-585, 1989.
 31. Pozzilli P, Kolb H. Immunotherapy in type 1 diabetes: present status. *Immunol Today*. 10(10):321-2, 1989.
 32. Kolb H, Bach JF, Eisenbarth GS, Harrison LC, Maclaren NK, Pozzilli P, Skyler JS, Stiller CR. Criteria for immune trials in type I diabetes. *Lancet*. 16;2(8664):686, 1989.
 33. Bach JF, Dupré J, Eisenbarth GS, Harrison LC, Maclaren NK, Nerup J, Pozzilli P. Immunotherapy in pre-type 1 diabetes mellitus. *Diabetologia*. 33(12):741, 1990.
 34. Sinagra D. Semifasting and type II diabetes mellitus. *Recenti Prog Med*. Feb;81(2):79-82, 1990.
 35. Di Cianni G, Benzi L, Ciccarone AM, Cecchetti P, Giannarelli R, Penno G, Navalesi R. Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations. *Clin Ter*. 134: 187-91, 1990.
 36. Mancini G, Parillo M: Lipid Intake and Atherosclerosis. *Ann Nutr Metab* 35:103-108, 1991.
 37. Vigneri R., Trischitta V., Italia S, Mazzarino S., Rabuazzo M.A., Squatrito . Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. *Diabete Metab* 17: 232-234, 1991.
 38. Parillo M, Rivellese A. A., Ciardullo A. V, Capaldo B., Giacco A, Genovese S., Riccardi G A high monounsaturated-fat/low-CHO diet improves peripheral insulin sensitivity in non insulin dependent diabetic patients. *Metabolism* 41: 1373-1378, 1992.

39. Trischitta V., Italia S., Mazzarino S., Buscema M, Rabuazzo A.M., Sangiorgio L., Squatrito S, Vigneri R. Comparison of combined therapies in treatment of secondary failure to glyburide. *Diabetes Care* 15: 539-542, 1992.
40. Parillo M, Mura A., Iovine C., Rivellese A., Iavicoli M, Riccardi G. Prevention of early morning hyperglycemia in insulin-dependent diabetic patients with long acting Zn-insulin. *Diabetes Care* 15, 12: 173-177, 1992.
41. Bonora E., Moghetti P., Querenza M., Zenere M., Cacciatori, V., Tosi F., Travia D., Zoppini G., Muggeo M. Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. *J. Endocrinol. Invest.* 14: 1-11, 1992.
42. Coscelli C., Calabrese G., Fedele D., Pisu E., Calderini C., Bistoni S., Lapolla A., Mauri M.G., Rossi A., Zappella A. Use of premixed insulin among the elderly. Reduction of errors in patients preparation of mixture.. *Diabetes Care* 15 (11), 1628-1630, 1992.
43. Pozzilli P, Signore A, Andreani D. What future for therapeutic prevention of type 1 (insulin-dependent) diabetes mellitus? *Diabetologia.* 35(11):1093-5, 1992.
44. Visalli N, Pozzilli P, Boccuni ML, Suppa MA, Messina R, Buzzetti R, Andreani D. Immunointervention in insulin dependent diabetes: implications for the epidemiology of the disease. *Ann Ig.* 4(3):159-63, 1992.
45. Krug J, Lampeter EF, Williams AJ, Procaccini E, Cartledge C, Signore A, Beales PE, Pozzilli P. Immunotherapy with ciamexon in the non obese diabetic (NOD) mouse. *Horm Metab Res.* 24(1):1-4, 1992.
46. Leslie RD, Carotenuto P, Pozzilli P. New developments in non-specific and semi-specific immunosuppression in type I diabetes. *Diabetes Metab Rev.* 9(4):257-67, 1993.
47. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. *Diabetes Care.* 16(10):1387-90, 1993.
48. Scavini M, Pincelli AI, Cruciani C, Giberti B, Orsi E, Galimberti G, Petrella G, Cristallo M, Pozza G, Micossi P. Influence of meal ingestion on insulin profiles following intraperitoneal delivery. *Metabolism.* 42:1013-1016, 1993.
49. Giugliano D, De Rosa N, Marfella R, Di Maro G, Cacciapuoti F, Quatraro A, Acampora R, D'Onofrio F. Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. *American Journal of Hypertension.* 6(11 Pt 1):927-32, 1993.
50. Pozzilli P, Maclaren NK. Immunotherapy at clinical diagnosis of insulin-dependent diabetes: an approach still worth considering. *Trends Endocrinol Metab.* 4(3):101-5, 1993.

51. Muir A, Schatz DA, Pozzilli P, MacLaren NK. Intervention therapies for insulin-dependent diabetes. *Autoimmunity*. 16(4):301-10, 1993.
52. Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L, et al. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study. *Diabetes Care*. 17(8):897-900, 1994.
53. Pozzilli P, Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Fioriti E, Signore A, Cavallo MG, Andreani D, Lucentini L, et al. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. *Diabet Med*. 11(1):98-104, 1994.
54. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. *Diabetologia*. 37(7):713-20, 1994.
55. Pampanelli S, Torlone E, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. *Diabetes Care*. 18(11):1452-9, 1995.
56. Parillo M., Riccardi G Dietary carbohydrate and glucose metabolism in diabetic patients. *Diabete e Metabolisme* 21:391-401,1995.
57. Pozzilli P, Visalli N, Buzzetti R, Baroni MG, Boccuni ML, Fioriti E, Signore A, Mesturino C, Valente L, Cavallo MG, et al. Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. *Diabete Metab*. 21(1):47-9, 1995.
58. Letizia C, d'Ambrosio C, De Ciocchis A, Scavo D, Pozzilli P. Serum angiotensin-converting enzyme levels in patients with recent-onset insulin-dependent diabetes after one year of low-dose cyclosporin therapy. IMDIAB Study Group. *Int J Clin Pharmacol Res*. 15(5-6):209-13, 1995.
59. Trevisan R, Tiengo A., Fedele D., Lapolla A and the North-East Italy Microalbuminuria Study Group. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non insulin dependent diabetic patients. *Am. J. Hypertens*. 8: 876-883, 1995.
60. Fallucca F, Sciuillo E, Maldonato A. Combined therapy with insulin and sulfonylureas for the treatment of new-onset insulin-dependent diabetes mellitus. *Horm Metab Res* 28: 86-88, 1996.

61. Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R, Giugliano D. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. *Diabetes Care*. 19(9):934-9, 1996.
62. Cusi K., Consoli A., De Fronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. *J Clin Endocr. Metab.*, 81:4012-4019, 1996.
63. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. *Diabetes Care*. 19(12):1357-63, 1996.
64. Signore A, Fiore V, Chianelli M, Procaccini E, Barone R, Ronga G, Negri M, Pozzilli P. The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes. *Diabetes Res Clin Pract*. 33(2):83-7, 1996.
65. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. *Diabetes Care*. 19(9):945-52, 1996.
66. Pozzilli P, Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Romiti A, Giovannini C, Lucentini L, Matteoli MC, Crinò A, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Suppa M, Sulli N, De Mattia G, Faldetta MR. Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). *Eur J Endocrinol*. 137(3):234-9, 1997.
67. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. *Ann Intern Med*. 126(12):955-9, 1997.
68. Pozzilli P. BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group. *Lancet*. 24;349(9064):1520-1, 1997.
69. De Toni S, Piva E, Lapolla A, Fontana G, Fedele D, Plebani M. Respiratory burst of neutrophils in diabetic patients with periodontal disease. *Ann N Y Acad Sci*. 15;832:363-7, 1997.
70. Giacco R, Brighenti F, Parillo M, Rivellese A, Riccardi G. Potato Dumplings elicit a low plasma glucose response in NIDDM patients. *Diabetes Care* 20,460, 1997.
71. Trischitta V., Italia S., Raimondo M., Guardabasso V, Licciardello C., Runello F, Mazzarino S., Sangiorgi L., Anello M., Vigneri R. Efficacy of combined treatments in

- NIDDM patients with secondary failure to sulphonilureas. Is it predictable? *J Endocrinol Invest* 21;744-747, 1998.
72. Giacco R., Brighenti F., Parillo M et al.. Are the beneficial metabolic effects of fibre enriched foods preserved when consumed within a composite meal? *Diabetes Nutrition & Metabolism* 130-137, 1998.
 73. Sinagra D, Scarpitta AM, Amato M Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. *Eur Rev Med Pharmacol Sci.* 2(5-6):175-9, 1998.
 74. Torlone E. Recombinant human insulin analogues: recommendations for optimal use. *BioDrugs.* 9(5):363-74, 1998.
 75. Fontana G., Lapolla A., Sanzari M., Piva E., Mussap M., De S Toni., Plebani M, Fusetti F., Fedele D An immunological evaluation of type 2 diabetic patients with periodontal disease. *Journal Diabetes and its Complications* 13: 13-23, 1999.
 76. Riccardi G, Giacco R., Parillo M et al Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. *Diabetic Medicine* 16,228-32, 1999.
 77. Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Lucentini L, Matteoli MC, Crinò A, Corbi S, Spera S, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Sulli N, Cervoni M, De Mattia G, Faldetta MR, Boscherini B, Pozzilli P, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). *Diabetes Metab Res Rev.* 15(3):181-5, 1999.
 78. Beales PE, Pozzilli P. Caution is required with interferon alpha as a potential treatment for type I diabetes. *Diabetologia.* 42(3):385, 1999.
 79. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. *Diabetes Care.* 22(5):795-800, 1999.
 80. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. *Diabetes Care.* 22(3):468-77, 1999.
 81. Pozzilli, P., Pitocco, D., Visalli, N., Cavallo, M.G., Buzzetti, R., Crinò, A., Spera, S., Giordano C., Sbriglia M, Sarugeri E, Ghirlanda, G No effect of oral insulin on residual beta-

cell function in recent-onset Type I diabetes (the IMDIAB VII). *Diabetologia* 43 (8) , pp. 1000-1004, 2000.

82. Gentili P, Maldonato A, Bloise D, Burla F, Coronel G, Di Paolantonio T. Personality variables and compliance with insulin therapy in type 2 diabetic subjects. *Diabetes Nutr Metab* 13: 1-6, 2000.
83. Giacco R, Parillo M, Rivellese AA, Lasorella G, Giacco A, D'Episcopo L, Riccardi G. Long term dietary treatment with increased amounts of fiber rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. *Diabetes Care* 23,1461-66, 2000.
84. Giacco R, Brighenti F, Parillo M, Capuano M, Ciardullo AV, Riveccio A, Rivellese AA, Riccardi G. Characteristics of some wheat-based foods of the Italian diet in relation to their influence on post prandial glucose metabolism in patients with type 2 diabetes. *British Journal of Nutrition* 85,33-40, 2001.
85. Gentili P, Maldonato A, Grieco R, Santini A. Influence of patients' representations and beliefs about diabetes and its treatment on their adherence to therapy. *Diab Nutr Metab*; 14: 140-152, 2001.
86. Annunzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Costelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. *Nutr Metab Cardiovasc Dis*, 11: 168-175, 2001.
87. Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano C, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G. Preprandial combination of Lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients. A multicenter randomized crossover trial. *NMCD* 11(3), 168-175, 2001.
88. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. *Diabetic Medicine* 19,119-24, 2002.
89. Gualdiero P, Esposito K, Ciotola M, Marfella R, Giugliano D. Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. *J Endocrinol Invest*. 25(6):RC16-8, 2002.

90. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. *Diabetes Metab Res Rev.* 18(2):114-7, 2002.
91. Nodari S, Metra M, Dei Cas A, Dei Cas L. Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. *Eur J Heart Fail.* 5(6):803-9, 2003.
92. Pozzilli P, Crinò A, Schiaffini R, Manfrini S, Fioriti E, Coppolino G, Pitocco D, Visalli N, Corbi S, Spera S, Suraci C, Cervoni M, Matteoli MC, Patera IP, Ghirlanda G; IMDIAB Group. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). *Diabetes Technol Ther.* 5(6):965-74, 2003.
93. Mosca A, Paleari R.A, Ceriotti F, Lapolla A, Fedele D for the Lecarnidipine Study Group. Biological variability of albumin excretion rate and albumin-to-creatinine ratio in hypertensive type 2 diabetic patients. *Clin Chem Lab Med* 41(9):1229-33, 2003.
94. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. *Diabetes Care.* 26(5):1490-6, 2003.
95. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. *Diabet Med.* 21(11):1213-20, 2004.
96. Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. *Clin Ther.* 4:502-10. 2004.
97. Consoli A, Gomis R, Salimi S, Home PD, Mehnert H, Strojek K, van Gaal LF: Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. *Diabetes Metab*, 30: 509-516, 2004.
98. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction

- and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA*. 292(12):1440-6, 2004.
99. Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lecanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria. DIAL Study (Diabete, Ipertensione, Albuminuria, Lecanidipina). *Diab Nutr Metab* 17(5): 259-266, 2004.
 100. Crinò A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, Suraci C, Pitocco D, Spera S, Corbi S, Matteoli MC, Patera IP, Manca Bitti ML, Bizzarri C, Pozzilli P; IMDIAB group. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). *Eur J Endocrinol*. 150(5):719-24, 2004.
 101. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. *Diabetes Res Clin Pract*. 68:S22-S29, 2005.
 102. Laviola, L., Cignarelli A, Giorgino F.. Clinical view on the need to develop new anti-diabetic drugs. *Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents* 5:469-474, 2005.
 103. Veneri D., Franchini M., Bonora E. Regression of type 2 diabetes with imatinib? *N. Engl. J. Med*. 352: 1049-1050, 2005 .
 104. Crinó A, Schiaffini R, Ciampalini P, Suraci MC, Manfrini S, Visalli N, Matteoli MC, Patera P, Buzzetti R, Guglielmi C, Spera S, Costanza F, Fioriti E, Pitocco D, Pozzilli P; IMDIAB Group. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 18(8):749-54, 2005.
 105. Restivo D.A., Marchese-Ragona R., Lauria G., Squatrito S., Gullo D., Vigneri R. Botulinum Toxin Treatment or Oropharyngeal Dysphagia Associated With Diabetic Neuropathy. *Diabetes Care* 29: 2650-2653, 2006.
 106. Pozzilli P, Guglielmi C. Immunomodulation for the prevention of SPIDDM and LADA. *Ann N Y Acad Sci*. 1079:90-8, 2006.
 107. Pitocco D, Crinò A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, Anguissola GB, Visalli N, Suraci C, Matteoli MC, Patera IP, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). *Diabet Med*. 23(8):920-3, 2006.
 108. Kautzky-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G. Insulin sensitivity during oral glucose tolerance test and its relations to

- parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. *Diabetes Obes Metab.* 8(5):561-7, 2006.
109. Federici MO, Mosca A, Testa R, Lapolla A, Andreani P, Benedetti MM, National survey on the execution of the oral glucose tolerance test (OGTT) in a representative cohort of Italian laboratories. *Clin Chem Lab Med.* 44:567-573, 2006.
 110. Giorgino, F., L. Laviola, A. Natalicchio, A., Leonardini. GLP-1: a new approach for type 2 diabetes therapy. *Diabetes Research and Clinical Practice* 74S2:S152-155, 2006.
 111. Giorgino, F., Natalicchio A., Leonardini A, Laviola L.. Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. *Diabetes Research and Clinical Practice* 78S:S59–S67, 2007.
 112. Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. *Int. J. Clin. Pract.* 154, suppl: 19-28, 2007.
 113. Lighthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in Clinical Practice *Clinical Therapeutics* 29: 1284-1292, 2007.
 114. Pozzilli P. Immuno-intervention and preservation of beta-cell function in type 1 diabetes. *Diabetes Metab Res Rev.* 23(4):255-6, 2007.
 115. Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH, Andreoli AM, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. *Diabetes Care* 30(5):1261, 2007.
 116. Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P.: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 9:186-193, 2007.
 117. Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P.: Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to on-going metformin on 24-hour 24-hour glycemic control and Beta-cell function in patients with type 2 diabetes. *Diabetes Obesity and Metabolism* 9:186-193, 2007.
 118. Basu R., Dalla Man C., Campioni M., Basu A., Nair K S., Jensen M.D., Khosla S., Klee G., Toffolo G., Cobelli C., Rizza R.A.: Two years of treatment with dehydroepiandrosterone does not improve insulin secretion action or postprandial glucose turnover in elderly men or women. *Diabetes* 56:753-66, 2007.

119. Del Prato S, Bianchi C, Miccoli R, Penno G. Pharmacological intervention in prediabetes: considering the risks and benefits. *Diabetes Obes Metab*; 9 Suppl 1: 17-22., 2007.
120. Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. *Horm Metab Res*. 39(11):826-9, 2007.
121. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. *Arch Physiol Biochem*. 114(1):3-10, 2008.
122. Marfella R, Barbieri M, Paolisso G. Insulin therapy and lipid overload in type 2 diabetes. *JAMA*. 300(7):789, 2008.
123. Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. *Diabet Med*. 25(11):1259-67, 2008.
124. Ravikumar B., Gerrard J., Dalla Man C., Firkbank M.J., Lane A., English P.T., Cobelli C., Taylor R.: Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. *Diabetes* 57:2288-95, 2008.
125. Xu L., Dalla Man C., Charbonnel B., Meninger G., Davies M.J., Williams-Herman D., Cobelli C., Stein P.P.: Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. *Diabetes Obes. Metab*. 10:1212-20, 2008.
126. Azuma K., Rádiková Z., Mancino J., Toledo F.G., Thomas E., Kangani C., Dalla Man C., Cobelli C., Holst J.J., Deacon C.F., He Y., Ligueros-Saylan M., Serra D., Foley J.E. Kelley D.E. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab*. 93:459-64, 2008.
127. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. *Diabetes Care*. 31(10):1966-71, 2008.
128. Pitocco D, DiStasio E, Crinò A, Manfrini S, Guglielmi C, Visalli N, Suraci C, Matteoli MC, Cavallo MG, Bizzarri C, Pozzilli P; IMDIAB Group. Age at diagnosis of type 1 diabetes and the effect of immunomodulatory therapies on residual beta cell function. *Horm Metab Res*. 40(1):66-8, 2008.

129. Chianelli M, Parisella MG, Visalli N, Mather SJ, D'Alessandria C, Pozzilli P, Signore A; IMDIAB study group. Pancreatic scintigraphy with ^{99m}Tc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. *Diabetes Metab Res Rev.* 24(2):115-22, 2008.
130. Bianchi C, Penno G, Daniele G, Benzi L, Del Prato S, Miccoli R. Optimizing management of metabolic syndrome to reduce risk: focus on life-style. *Intern Emerg Med.*; 3: 87-98, 2008.
131. Bossi AC, Ansah EO. Bent needles: another problem in glycaemic control. *Diabetes Care* 31(10):e70, 2008.
132. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, Rabuazzo AM, Piro S, Alagona C, Spadaro L, Purrello F, Pezzino V. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. *Acta Diabetol* 45:53-59, 2008.
133. Imbergamo, M.P., Amato, M.C., Sciortino, G., Gambina, M., Accidenti, M., Criscimanna, A., Giordano, C., Galluzzo, A Use of glargine in pregnant women with Type 1 diabetes mellitus: A case-control study. *Clinical Therapeutics* 30 (8):1476-1484, 2008.
134. Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). *Clin Endocrinol (Oxf)*. 69(6):963-9, 2008.
135. Valensi P, Benroubi M, Borzì V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M Wenying Y. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. *International Journal of Clinical Practice*; 62;1809-1819, 2008.
136. Shah S, Benroubi M, Borzì V, Gumprecht J, Kawamori R, Shaban J, Shestakova M Wenying Y Valensi P. Safety and effectiveness of biphasic insulin aspart 30/70(NovoMix30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study *International Journal of Clinical Practice*; 63: 574-582, 2009.
137. Marfella R, Portoghese M, Ferraraccio F, Siniscalchi M, Babieri M, Di Filippo C, D'Amico M, Rossi F, Paolisso G. Thiazolidinediones may contribute to the intramyocardial lipid accumulation in diabetic myocardium: effects on cardiac function. *Heart*. 95(12):1020-2, 2009.
138. Dalla Man C., Bock G., Giesler P.D., Serra D.B., Ligueros Saylan M., Foley J.E., Camilleri M., Toffolo G., Cobelli C., Rizza R.A, Vella A.: Dipeptidyl peptidase 4 inhibition

- by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. *Diabetes Care* 32:14-8, 2009.
139. Valensi P, Benroubi M, , Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y. Initiating insulin therapy with, or switching existing insulin therapy to biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study *International Journal of Clinical Practice* 63: 522-531, 2009.
 140. Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, Sbraccia P, Federici M, Quon MJ, Lauro D. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. *Atherosclerosis*. 206(2):569-74, 2009.
 141. Gumprecht J, Benroubi M, Borzi V, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, Lighthelm RJ, Valensi P. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study *Int J Clin Pract*;; 63:966-972, 2009.
 142. Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Lighthelm RJ, Valensi P. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study *Current Medical Research Opinion* 25(11): 2643-2654, 2009.
 143. Del Prato S, Penno G, Miccoli R. Changing the treatment paradigm for type 2 diabetes. *Diabetes Care*;; 32 Suppl 2: S217-22, 2009.
 144. Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. *Diabetes Care*;; 32 Suppl 2: S342-8, 2009.
 145. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. *Nutr Metab Cardiovasc Dis*. 19(8):571-9, 2009.
 146. Mannarino E, Pirro M., Cortese C., Lupattelli G., Siepi D., Mezzetti A, Bertolini S., Parillo M, Fellin R., Pujia A., Averna M., Nicolle C., Notarbartolo A. Effects of a phytosterol-enriched dairy product on lipids, sterols, and 8-isoprostane in

- hypercholesterolemic patients: A multicenter Italian study. *Nutrition, Metabolism and Cardiovascular Diseases* 19, 84-90, 2009.
- 147.** Iannuzzi A,. Licenziati MR,.Vacca M,. De Marco D, Cinquegrana G,. Laccetti M, Bresciani A,. Covetti G,. Iannuzzo G, Rubba P,. Parillo M: Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. *Heart Vessels* 24(6):419-424, 2009.
- 148.** Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, Pacini G, Ludvik B. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). *Horm Metab Res.* 41(7):573-9, 2009.
- 149.** Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. *Nutr. Metab. Cardiovasc. Dis.* 19(1):45-53, 2009.
- 150.** Cernea S, Buzzetti R, Pozzilli P. Beta-cell protection and therapy for latent autoimmune diabetes in adults. *Diabetes Care.* 32 Suppl 2:S246-52, 2009.
- 151.** Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP; D-Cure Workshop Challenges in developing endpoints for type 1 diabetes intervention studies. *Diabetes Metab Res Rev.* 25(8):694-704, 2009.
- 152.** Pozzilli P, Leslie RD. New prospects for immunotherapy at diagnosis of type 1 diabetes. *Diabetes Metab Res Rev.* 25(4):299-301, 2009.
- 153.** Khoo CP, Valorani MG, Brittan M, Alison MR, Warnes G, Johansson U, Hawa M, Pozzilli P Characterization of endothelial progenitor cells in the NOD mouse as a source for cell therapies. *Diabetes Metab Res Rev.* 25(1):89-93, 2009.
- 154.** Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). *The Lancet* 374, 39-47, 2009.
- 155.** Sesti G. Harnessing the weight-regulating properties of GLP-1 in the treatment of type 2 diabetes. *Diabetes Obes Metab.* 11 (Suppl. 3): 4-10, 2009.
- 156.** Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. *Clin Ther* 31:2472-2488, 2009.

157. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; for the Liraglutide Effect and Action in Diabetes (LEAD)-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. *Diabetes Care* 33:1300-1303, 2010.
158. Balasubramanian R., Gerrard J., Dalla Man C., Firbank M.J., Lane A., English P.T., Cobelli C., Taylor R.: Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content. *Diabetic Medicine* 27:150-156, 2010.
159. Bock G., Dalla Man C., Micheletto F., Basu R., Giesler P.D., Laugen J., Deacon C.F., Holst J.J., Toffolo G., Cobelli C., Rizza R.A., Vella A.: The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. *Clinical Endocrinology* 73: 189-196, 2010.
160. Fadini GP, Albiero M, Menegazzo L, Boscaro E, Pagnin E, Iori E, Cosma C, Lapolla A, Pengo V, Stendardo M, Agostini C, Pelicci P, Giorgio M, Avogaro A. The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing. *Diabetes* 59 (9): 2306-14, 2010 .
161. Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesaro M, Lauro D. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. *Atherosclerosis*. 210(1):199-201, 2010.
162. Ruggerenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Perna A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, and Remuzzi G for the Ezetimibe and Simvastatin in dyslipidemia of Diabetes (ESD) Study Group. Effects of combined Ezetimibe and Simvastatin Therapy as compared to Simvastatin alone in Patients with Type 2 Diabetes: a Prospective, Randomized, Double-Blind, Clinical Trial. *Diabetes Care* 33:1954-1956, 2010.
163. Pratley RE, Nauck M, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not Have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open trial *Lancet* 375: 1447-1456, 2010.
164. Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). *Cardiovasc Diabetol.* 21; 9: 20, 2010.

165. Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. *Am J Cardiol.* 106(9):1292-6, 2010.
166. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. *Drugs.*70(1):41-56, 2010.
167. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. *Diabetologia* 53:1743-53, 2010.
168. Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. *Acta Diabetol.* 47:271-78, 2010.
169. Marfella R, Luongo C, Coppola A, Luongo M, Capodanno P, Ruggiero R, Mascolo L, Ambrosino I, Sardu C, Boccardi V, Lettieri B, Paolisso G. Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients. *Atherosclerosis.* 208(2):473-9, 2010.
170. Fatati G, Cortinovis F, Fontana L, Fusco MA, Leotta S, Marelli G, Mirri E, Parillo M.; Sukkar SG, Tagliaferri M, Tomasi F, Tubili C. ADI-AMD recommendations on insulin treatment during artificial nutrition. *Mediterr J Nutr Metab.*3 1-8, 2010.
171. Marfella R, Paolisso G. Reply to the "Comments on the article 'Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations'", by Avogaro (*Journal of Diabetes and Its Complications* 25 [2011] 352-353). *J Diabetes Complications.* 25(6):405-6, 2011.
172. Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. *Diabetes Care.* 34 Suppl 2: S231-S235, 2011.
173. Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. *J Endocrinol Invest.*; 34:69-77, 2011.
174. Bellomo Damato A, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. *Diabet Med.*; 28:560-566, 2011.
175. Busetto L, Sbraccia P, Frittitta L, Pontiroli AE. The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions. *Obes Surg.* 21(9):1451-7, 2011.
176. Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in

- type 2 diabetes patients: a prospective randomized open-label trial. *Diabetes Obes Metab.* 13(12):1149-57, 2011.
177. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, Federici M. Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. *Atherosclerosis.* 215(1):180-3, 2011.
178. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. *Diabetes Obes Metab.* 13(11):1008-19, 2011.
179. Sesti G. Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists. *Diabetes Care* 34 (Suppl. 2), S272-275, 2011.
180. Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. *Endocr Pract* 17: 906-13, 2011.
181. Pozzilli P. Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. *Nat Rev Endocrinol.* 20;8(2):78-80, 2011.
182. Pozzilli P, Guglielmi C, Maggi D, Carlone A, Buzzetti R, Manfrini S. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes. *Curr Pharm Des.* 17(29):3224-8, 2011.
183. Tuccinardi D, Fioriti E, Manfrini S, D'Amico E, Pozzilli P. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes. *Expert Opin Biol Ther.* 11(9):1233-40, 2011.
184. Metra M, Bettari L, Carubelli V, Bugatti S, Dei Cas A, Del Magro F, Lazzarini V, Lombardi C, Dei Cas L. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. *Drugs.* 71(5):515-25, 2011.
185. Nosso G, Angrisani L, Saldalamacchia G, Cutolo PP, Cotugno M, Lupoli R, Vitolo G, Capaldo B. Impact of sleeve gastrectomy on weight loss, glucose homeostasis, and comorbidities in severely obese type 2 diabetic subjects. *J Obes.* 2011:340867, 2011.
186. Bonfante L, Virga G, Lapolla A, Toffolo K, Del Prete D, Scaparrotta G, Alessi M, D'Angelo A. Suspension of ACE-I and ARB Treatment Is Associated with Acute Increase in Serum AGE Levels in Patients on Peritoneal Dialysis. *Perit Dial Int.* 31(1):94-7, 2011.
187. Orioli M, Vistoli G, Regazzoni L, Pedretti A, Lapolla A, Rossoni G, Canevotti R, Gamberoni L, Previtali M, Carini M, Aldini G. Design, Synthesis, ADME Properties, and Pharmacological Activities of β -Alanyl-D-histidine (D-Carnosine) Prodrugs with Improved Bioavailability. *ChemMedChem.* 6(7): 1279-82, 2011.

- 188.** Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects. *Expert Opin Pharmacother.* 12(16):2449-55, 2011. *Erratum in: Expert Opin Pharmacother.* 2011 Dec;12(17):2765.
- 189.** Bruno G, De Micheli A, Frontoni S, Monge L; Società Italiana di Diabetologia- Associazione Medici Diabetologi (SID-AMD) Working Group on the Standards of Care for Diabetes. Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". *Nutr Metab Cardiovasc Dis.* 21:302-14, 2011.
- 190.** Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. *Eur J Clin Pharmacol* 67:289-299, 2011.
- 191.** Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. *Diabetes Care* 34(12):2524-6, 2011.
- 192.** Irace C, Fiorentino R, Carallo C, Scavelli F, Gnasso A. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. *Diabetes Technol Ther* 13:1261-1263, 2011.
- 193.** Parillo M, Annuzzi G, Rivellese AA, Bozzetto L, Alessandrini R, Riccardi G, Capaldo B. Effects of meals with different glycaem index on postprandial blood glucose response in patients with Type 1 diabetes treated with continuous subcutaneous insulin infusion *Diabetic Medicine.* 227 – 229, 2011.
- 194.** Consoli A. New therapeutic algorithm of Type 2 diabetes: Lights and shadows. *J Endocrinol Invest.* 34(1):65-8, 2011.
- 195.** Pozzilli P, Strollo R. Immunotherapy for Type 1 diabetes: getting beyond a negative first impression. *Immunotherapy.* 4(7):655-8, 2012.
- 196.** Paolisso G, Monami M, Marfella R, Rizzo MR, Mannucci E. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? *Adv Ther.* 29(3):218-33, 2012.
- 197.** Roth J, Pozzilli P. Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". *Diabetes Metab Res Rev* 2012. *Diabetes Metab Res Rev.* 28(4):325, 2012.

- 198.** Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition. *Diabetes Care*. 35(10):2076-82, 2012.
- 199.** Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, Quon MJ, Sbraccia P, Federici M, Tesauro M, Cardillo C, Lauro D. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. *Atherosclerosis*. 223(1):197-203, 2012.
- 200.** Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, Carbonara O, Gualdiero P, Petronella P, Ferraraccio F, Petrella A, Canonico R, Campitiello F, Della Corte A, Paolisso G, Canonico S. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. *Exp Diabetes Res*.2012:892706, 2012.
- 201.** Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Åman J, Kärde G, Neiderud Helsingborg J, Lundström G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanås R, Larsson K, Rathsmann B, Forsgren H, Desaix H, Forsander G, Nilsson NÖ, Åkesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A, Rica I, Barrio R, Clemente M, López Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. *N Engl J Med*. 2;366(5):433-42, 2012.
- 202.** Parillo M., Licenziati MR, Vacca M, DeMarco D, Annuzzi A. Metabolic Changes after Hypocaloric, Low Glycemic Index diet in obese children. *J Endoc Investigation* 35,629-33, 2012.
- 203.** Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, Riccardi G, Rivellese AA. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. *Diabetes Care*. 35(7):1429-35, 2012.
- 204.** Annuzzi G, Della Pepa G, Vetrani C. Vitamin D and Cardiovascular Disease: Is There Evidence to Support the Bandwagon? *Curr Atheroscler Rep*.14(6):525-34, 2012.

- 205.** Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. *Diabetes Obes Metab.* 14(5):433-46, 2012.
- 206.** Palermo, Maddaloni E., Pozzilli P, Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence? *Expert Opinion on Biological Therapy*, vol. 12, no. 6, pp. 767–72, 2012.
- 207.** Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol.* 49:193-197, 2012.
- 208.** Bolli GB, Consoli A, Giaccari A. Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. *Nutr Metab Cardiovasc Dis.* 22(12):1007-12, 2012.
- 209.** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2012;35:1364-1379. *Diabetes Care.* 35:e71, 2012.
- 210.** Giaccari A, Giorda CB, Riccardi G, De Micheli A, Bruno G, Monge L, Frontoni S. Evaluation of guidelines on diabetes medication. *Ann Intern Med.* 156:752-3, 2012.
- 211.** Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. NN1250-3582 (BEGIN BB T2D) Trial Investigators. *Lancet* 21; 379(9825):1498-507, 2012.
- 212.** Vaccaro O., Masulli M., Bonora E., Del Prato S., Nicolucci A., Rivellese A.A., Riccardi G. on behalf of the TOSCA.IT Study Group. The TOSCA.IT Trial: A study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. *Diabetes Care* 35:e82, 2012.
- 213.** Vaccaro O., Masulli M., Bonora E., Del Prato S., Giorda C.B., Maggioni A.P., Mocarelli P., Nicolucci A., Rivellese A.A., Squatrito S., Riccardi G.; on behalf of the TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients

- inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. *Nutr. Metab. Cardiovasc. Dis.* 22: 997-1006, 2012.
214. Borzi V Benroubi M, , Gumprecht J Kawamori R Lighthelm RJ, Shaban J, Shah S, Shestakova M, , Wenying Y Valensi P Predictors of postprandial blood glucose response to biphasic insulin analogue therapy *Prim. Care Diab.*; 7; 63- 67, 2012.
 215. Giorda CB, Mulas MF, Manicardi V, Suraci C, Guida P, Marafetti L, Nada E, Gentile S Factors associated with a rapid normalization of HbA_{1c} in newly diagnosed type 2 diabetes patients seen in a specialist setting. *Acta Diabetologica* 09, 2012.
 216. DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group (Orsi E). Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. *Diabetes Care.* 35:1446-1454, 2012.
 217. Valensi P, Shaban J, Benroubi M, Kawamori R, Borzi V Shah S Wenying Y, Prusty V, Hansen JB Gumprecht J Predictors of achieving HbA_{1c} <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study *Current Medical Research and Opinion*;; 29: 601-609, 2013.
 218. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N, Barini A, Pitocco D, Ghirlanda G, Lauro D, Campia U, Cardillo C. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. *Diabetes Care.* 36(3):683-9, 2013.
 219. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. *Atherosclerosis.* 227(2):349-54, 2013.
 220. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research. *Diab Vasc Dis Res* 10:72-77, 2013.
 221. Boccardi V, Barbieri M, Rizzo MR, Marfella R, Esposito A, Marano L, Paolisso G. A new pleiotropic effect of statins in elderly: modulation of telomerase activity. *FASEB J.* 27(9):3879-85, 2013.
 222. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. *Diabetes Metab Syndr Obes.*; 6: 161-170, 2013.
 223. Opinto G, Natalicchio A, Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. *Arch Physiol Biochem*; 119: 170-8, 2013.

- 224.** Maggi S, Noale M, Pilotto A, Tiengo A, Cavallo Perin P, Crepaldi G; Metabolic Working Group. The METABOLIC Study: multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. *Diabetes Metab.*; 39:236-243, 2013.
- 225.** Consoli A, Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? *Diabetes Obes Metab.* 15(11):967-77, 2013.
- 226.** Beltramello G, Manicardi V, Trevisan R Trialogue : Managing hyperglycaemia in internal medicine: instructions for use. *Acta Diabetologica* 04, 2013.
- 227.** Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, Morano S, Ferrannini E, Pugliese G; Renal Insufficiency and Cardiovascular Events Study Group. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the renal insufficiency and cardiovascular events italian multicenter study. *J. Am. Geriatr. Soc.* 61:1253-1261, 2013.
- 228.** Micheletto F., Dalla Man C., Kolterman O., Chiquette E., Herrmann K., Schirra J., Kovatchev B., Cobelli C.: In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes. *Diabetes Technol Ther.* 15: 802- 809, 2013.
- 229.** King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1c targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1c <8.0%. *Endocr Pract* 19: 64-72, 2013.
- 230.** Ohlsson L, Alsalim W, Carr RD, Tura A, Pacini G, Mari A, Ahrén B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. *Diabetes Obes Metab.* 15(6):531-7, 2013.
- 231.** Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D; PRISMA study group, Egan CG, Chinae B, Bravi F, Di Pietro C. Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. *J Endocrinol Invest.* 36(8):606-16, 2013.
- 232.** Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. *Cell Death Dis.* 4:e612, 2013.
- 233.** Dardano A, Penno G, Del Prato S, Miccoli R. Optimal therapy of type 2 diabetes: a controversial challenge. *Aging (Albany NY).* 6: 187-206, 2014.

- 234.** Vetrani C, Rivellese AA, Annuzzi G, Mattila I, Meudec E, Hyötyläinen T, Orešič M, Aura A-M. Phenolic metabolites as compliance biomarker for polyphenol intake in a randomized controlled human intervention. *Food Research International*. 63:233-8, 2014.
- 235.** Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R. NIRAD Study Group. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*. 171(6):697-704, 2014.
- 236.** Bellia A, Babini AC, Marchetto PE, Arsenio L, Lauro D, Lauro R. Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. *Acta Diabetol*. 51(2):269-75, 2014.
- 237.** Khazrai YM, Maddaloni E, Altomare M., Cacciapaglia F, Pozzilli P New technologies aiding dietary programmes for weight control: the oral glucose spray. *Endocrine*, vol. 45, no. 2, pp. 288-292, 2014.
- 238.** Maddaloni E., Pozzilli P., Comment on: "Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. *Nutrition Metabolism and Cardiovascular Disease*, vol. 24, no. 1, p. e1, 2014.
- 239.** Maddaloni E., Pozzilli P., SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes)". *Endocrine*, vol. 46, no. 1, pp 3-5, 2014.
- 240.** Rizzo M, Chandalia M, Patti A, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. *Cardiovasc Diabetol* 13:49, 2014.
- 241.** Brunetti A, Brunetti FS, Chiefari E. Pharmacogenetics of type 2 diabetes mellitus: An example of success in clinical and translational medicine. *World J Transl Med*. 3: 141-149, 2014.
- 242.** Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). *Am J Cardiol*. 114(5):743-50, 2014.
- 243.** Tura A, Muscelli E, Gastaldelli A, Ferrannini E, Mari A. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. *Diabetologia*. 57(6):1199-203, 2014.

- 244.** Van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, Smith U, Diamant M. The effect of alogliptin and pioglitazone combination therapy on various aspects of β -cell function in patients with recent-onset type 2 diabetes. *Eur J Endocrinol.* 8;170(4):565-74, 2014.
- 245.** Brunetti A. Individualizing Care in Type 2 Diabetes Mellitus. *J Diabetes Metab Disord Control* 1: 00020, 2014.
- 246.** Muscogiuri G, Cignarelli A, Giorgino F, Prodrum F, Santi D, Tirabassi G, Balercia G, Modica R, Faggiano A, Colao A. GLP-1: benefits beyond pancreas. *J Endocrinol Invest.* . 38:115, 2015.
- 247.** Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R; Italian Study Group on Diffusion of CSII. Continuous subcutaneous insulin infusion in Italy: third national survey. *Diabetes Technol Ther.* 17(2):96-104, 2015.
- 248.** Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, Suraci C, Mulas MF, Napoli A, Rossi MC, Manicardi V. Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus. *Int J Endocrinol.*2015:957105, 2015.
- 249.** Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. *Nat Rev Endocrinol.* 11(5):289-97, 2015.
- 250.** Lindgren O, Pacini G, Tura A, Holst JJ, Deacon CF, Åhrén B. Incretin Effect after Oral Amino Acid Ingestion in Humans. *J Clin Endocrinol Metab.* 100:1172-6, 2015.
- 251.** Lapolla A, Frison V, Bettio M, DalPos M, Ronchini P, Panebianco G, Tadiotto F, DaTos V, D'Ambrosio M, Marangoni A, Ferrari M, Pianta A, Balzano S, Confortin L, Lamonica M, Marin N, Strazzabosco M, Brun E, Mesturino CA, Simoncini M, Zen F, Bax G, Bonsembiante B, Cardone C, Dalfrà MG, Gallo A, Masin M, Piarulli F, Sartore G, Simioni N. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting. *Clin Ther* S0149-2918(14)00829-7 , 2015.
- 252.** Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. *Expert Opin Drug Saf.*, 14:207-218, 2015.
- 253.** Ampudia-Blasco FJ, Benhamou PY, Charpentier G, Consoli A, Diamant M, Gallwitz B, Khunti K, Mathieu C, Ridderstråle M, Seufert J, Tack C, Vilsbøll T, Phan TM, Stoevelaar H. A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. *Diabetes Technol Ther.* 17:194-202, 2015.

- 254.** Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffo E, Lupoli R, Angrisani L, Riccardi G, Capaldo B. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. *Acta Diabetol.* 52:331-6, 2015.
- 255.** Rizzo M, Abate N, Chandalia M, Rizvi AA, Giglio RV, Nikolic D, Marino AG, Barbagallo I, Isenovic ER, Banach M, Montalto G, Volti GL. Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 And Ghrelin Levels In Patients With Type 2 Diabetes: a prospective pilot study. *J Clin Endocrinol Metab.* 100:603-6, 2015.
- 256.** Torre E, Colombo GL, Bruno GM, Valentino MC, Di Matteo S. Cost Analysis of the Diabetic Treatment in Italy: The Role of Vildagliptin vs. Other Therapeutic Options in Patients with Type 2 Diabetes with Renal Insufficiency. *Value Health.* 18(7):A609, 2015.
- 257.** Bruno GM, Valentino MC, Oselin M, Colombo GL, Di Matteo S. Comparison between HTA Reports in Veneto and Emilia Romagna: Drugs Assessment Decision Criteria and Priorities. *Value Health.* 18(7):A558, 2015.
- 258.** Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. *Cardiovasc Diabetol.* 14:142, 2015.
- 259.** Carallo C, Scavelli FB, Cipolla M, Merante V, Medaglia V, Irace C, Gnasso A; Progetto Diabete Calabria Management of Type 2 Diabetes Mellitus through Telemedicine. *PLoS One.* 10(5):e0126858, 2015.
- 260.** Vitaglione P, Mennella I, Ferracane R, Rivellese AA, Giacco R, Ercolini D, Gibbons SM, La Storia A, Gilbert JA, Jonnalagadda S, Thielecke F, Gallo MA, Scalfi L, Fogliano V. Whole-grain wheat consumption reduces inflammation in a randomized controlled trial on overweight and obese subjects with unhealthy dietary and lifestyle behaviors: role of polyphenols bound to cereal dietary fiber. *Am J Clin Nutr.* 101(2):251-61, 2015.
- 261.** Fanin A, Benetti A, Ceriani V, Pontiroli AE. Bariatric surgery versus medications in the treatment of type 2 diabetes. *Minerva Endocrinol.* 40(4):297-306, 2015.
- 262.** Pozzilli P, Maddaloni E, Buzzetti R. Combination immunotherapies for type 1 diabetes mellitus. *Nat Rev Endocrinol.* 11(5):289-97, 2015.
- 263.** Barchetta I, Guglielmi C, Bertocchini L, Calella D, Manfrini S, Secchi C, Pozzilli P, Cavallo MG; IMDIAB group. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. *Acta Diabetol.* 52(5):873-80, 2015.
- 264.** Ibrahim M, Abu Al Magd M, Annabi FA, Assaad-Khalil S, Ba-Essa EM, Fahdil I, Karadeniz S, Meriden T, Misha'l AA, Pozzilli P, Shera S, Thomas A, Bahijri S, Tuomilehto

- J, Yilmaz T, Umpierrez GE. Recommendations for management of diabetes during Ramadan: update 2015. *BMJ Open Diabetes Res Care*. 3(1):e000108, 2015.
- 265.** Defeudis G, Gianfrilli D, Di Emidio C, Pofi R, Tuccinardi D, Palermo A, Lenzi A, Pozzilli P. Erectile dysfunction and its management in patients with diabetes mellitus. *Rev Endocr Metab Disord*. 16: 213–231, 2015.
- 266.** Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, Guastamacchia E, Triggiani V. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. *Andrology*. 3(6):1094-103, 2015.
- 267.** Vitale M, Masulli M, Rivellese AA, Babini AC, Boemi M, Bonora E, Buzzetti R, Ciano O, Cignarelli M, Cigolini M, Clemente G, Citro G, Corsi L, Dall'Aglia E, Del Prato S, Di Cianni G, Dolci MA, Giordano C, Iannarelli R, Iovine C, Lapolla A, Lauro D, Leotta S, Mazzucchelli C, Montani V, Perriello G, Romano G, Romeo F, Santarelli L, di Cola RS, Squatrito S, Tonutti L, Trevisan R, Turco AA, Zamboni C, Riccardi G, Vaccaro O. Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes-The TOSCA.IT Study. *Eur J Nutr*. 55(4):1645-51, 2016.
- 268.** Vetrani C, Rivellese AA, Annuzzi G, Adiels M, Borén J, Mattila I, Orešič M, Aura AM. Metabolic transformations of dietary polyphenols: comparison between in vitro colonic and hepatic models and in vivo urinary metabolites. *J Nutr Biochem*. 33:111-8, 2016.
- 269.** Bozzetto L, Alderisio A, Giorgini M, Barone F, Giacco A, Riccardi G, Rivellese AA, Annuzzi G. Extra-Virgin Olive Oil Reduces Glycemic Response to a High-Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Care*. 39(4):518-24, 2016.
- 270.** Rizzo M, Rizvi AA, Patti AM, Nikolic D, Giglio RV, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S, Ceriello A. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. *Cardiovasc Diabetol*. 3;15(1):162, 2016.
- 271.** Cordera R, Adami GF. From bariatric to metabolic surgery: Looking for a "disease modifier" surgery for type 2 diabetes. *World J Diabetes*. 7(2):27-33, 2016.
- 272.** Marchetti L, Reali F, Dauriz M, Brangani C, Boselli L, Ceradini G, Bonora E, Bonadonna RC, Priami C. A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. *Sci Rep*. 6:36029, 2016.

- 273.** Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. *Cardiovasc Diabetol.* 11;15(1):111, 2016.
- 274.** Bonora E, Cigolini M. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. *Nutr Metab Cardiovasc Dis.* 26(4):273-84, 2016.
- 275.** Buzzetti R, Pozzilli P, Frederick R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). *Diabetes Metab Res Rev.* 32(3):289-96, 2016.
- 276.** Bonora E, Bryzinski B, Hirshberg B, Cook W. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. *Nutr Metab Cardiovasc Dis.* 26(5):374-9, 2016.
- 277.** Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. *Diabetes Metab Res Rev.* 32(8):776-790, 2016.
- 278.** Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care.* 39 Suppl 2:S187-95, 2016.
- 279.** Ahrén B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. *Diabetes Ther.* 7(3):583-90, 2016.
- 280.** Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A; Italian Society for Study of Diabetes (SID).; Italian Endocrinological Society (SIE). Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. *Nutr Metab Cardiovasc Dis.* 26(2):85-102, 2016.
- 281.** Maddaloni E, Pozzilli P. Why China guidelines for type 2 diabetes represent an opportunity for treating this disease. *Diabetes Metab Res Rev.* 32(5):438-9, 2016.
- 282.** Maddaloni E, D'Onofrio L, Pozzilli P. Frailty and geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy? *Diabetes Metab Res Rev.* 32(2):169-75, 2016.

- 283.** Penno G, Garofolo M, Del Prato S. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. *Nutr Metab Cardiovasc Dis.* 26(5):361-73, 2016.
- 284.** Hinshaw L, Schiavon M, Dadlani V, Mallad A, Dalla Man C, Bharucha A, Basu R, Geske JR, Carter RE, Cobelli C, Basu A, Kudva YC. Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes. *J Clin Endocrinol Metab.* 101(5):1954-62, 2016.
- 285.** Perseghin G, Solini A. The EMPA-REG outcome study: critical appraisal and potential clinical implications. *Cardiovasc Diabetol.* 15:85, 2016.
- 286.** Mangiacapra F, Panaioli E, Colaiori I, Ricottini E, Lauria Pantano A, Pozzilli P, Barbato E, Di Sciascio G. Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). *Circulation.* 134(11):835-7, 2016.
- 287.** Soare A, Del Toro R, Khazrai YM, Di Mauro A, Fallucca S, Angeletti S, Skrami E, Gesuita R, Tuccinardi D, Manfrini S, Fallucca F, Pianesi M, Pozzilli P. A 6-month follow-up study of the randomized controlled Ma-Pi macrobiotic dietary intervention (MADIAB trial) in type 2 diabetes. *Nutr Diabetes.* 6(8):e222, 2016.
- 288.** Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, Peano C, Turrone S, Rampelli S, Pozzilli P, Pianesi M, Fallucca F, Brigidi P. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. *Br J Nutr.* 116(1):80-93, 2016.
- 289.** Deiss D, Adolfsson P, Alkemade-van Zomeren M, Bolli GB, Charpentier G, Cobelli C, Danne T, Girelli A, Mueller H, Verderese CA, Renard E. Insulin Infusion Set Use: European Perspectives and Recommendations. *Diabetes Technol Ther.* 18(9):517-24, 2016.
- 290.** Guglielmi C, Williams SR, Del Toro R, Pozzilli P. Efficacy and safety of orelxizumab use in new-onset type 1 diabetes mellitus. *Expert Opin Biol Ther.* 16(6):841-6, 2016.
- 291.** Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, Atkin SL; Study 1821 Investigators. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. *Diabetes Care.* 39(2):231-41, 2016.
- 292.** Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T;

- SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 375(19):1834-1844, 2016.
- 293.** Vettoretti M, Facchinetti A, Sparacino G, Cobelli C. Predicting Insulin Treatment Scenarios with the Net Effect Method: Domain of Validity. *Diabetes Technol Ther.* 18(11):694-704, 2016.
- 294.** Fiorentino TV, Sesti G. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors. *Endocrine.* 53(2):373-80, 2016.
- 295.** Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. *Diabetes Care.* 39(8):1318-28, 2016.
- 296.** Santoboni F, Balducci S, D'Errico V, Haxhi J, Vetrano M, Piccinini G, Ferretti A, Pugliese G, Vulpiani MC. Extracorporeal Shockwave Therapy Improves Functional Outcomes of Adhesive Capsulitis of the Shoulder in Patients With Diabetes. *Diabetes Care.* 40(2):e12-e13, 2017.
- 297.** Ceriani V, Cetta F, Lodi T, Pinna F, Pontiroli AE. Clinical and Metabolic Effects of Biliopancreatic Diversion Persist After Reduction of the Gastric Pouch and Elongation of the Common Alimentary Tract. Preliminary Report in a Series of Patients with a 10-Year Follow-Up. *Obes Surg.* 27(6):1493-1500, 2017.
- 298.** Müller N, Khunti K, Kuss O, Lindblad U, Nolan JJ, Rutten GE, Trento M, Porta M, Roth J, Charpentier G, Jörgens V, Müller UA. Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study. *Acta Diabetol.* 54(2):209-214, 2017.
- 299.** Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A; DARWIN-T2D Network. Rationale and design of the DARWIN-T2D (Dapagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. *Nutr Metab Cardiovasc Dis.* 27(12):1089-1097, 2017.
- 300.** Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F,

- Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol.* 5(11):887-897, 2017.
- 301.** Maggi D, Bordone C, Briatore L, Cheli V, Fontana L, Mazzucchelli C, Montecucco F, Adami G, Cordera R. Glucose-targeted therapy for subjects with type 2 diabetes mellitus: primum non nocere. *Eur J Clin Invest.* 47(10):691-693, 2017.
- 302.** Adami GF, Cordera R Assessing the Actual Clinical Effectiveness of Metabolic/Bariatric Surgery for the Type 2 Diabetes Therapy. *Obes Surg.* 27(7):1886-1888, 2017.
- 303.** Scopinaro N, Adami GF, Bruzzi P, Cordera R. Prediction of Diabetes Remission at Long Term Following Biliopancreatic Diversion. *Obes Surg.* 27(7):1705-1708, 2017.
- 304.** Bonaventura A, Liberale L, Carbone F, Scopinaro N, Camerini G, Papadia FS, Cordera R, Dallegri F, Adami GF, Montecucco F. High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion. *Nutr Metab Cardiovasc Dis.* 27(5):423-429, 2017.
- 305.** Cacciatori V, Zoppini G, Bellavere F, Rigolon R, Thomaseth K, Pichiri I, Trombetta M, Dauriz M, De Santi F, Targher G, Santi L, Bonora E. Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. *J Endocr Soc.* 6;2(1):53-62, 2017.
- 306.** Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondur N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 17;377(7):644-657, 2017.
- 307.** Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E. Mechanisms linking empagliflozin to cardiovascular and renal protection. *Int J Cardiol.* 241:450-456, 2017.
- 308.** Avogaro A, Giaccari A, Fioretto P, Genovese S, Purrello F, Giorgino F, Del Prato S. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. *Expert Rev Clin Pharmacol.* 10(7):763-772, 2017.

- 309.** Ballotari P, Ferrari F, Ballini L, Chiarenza A, Manicardi V, Giorgi Rossi P. Lifestyle-tailored interventions for South Asians with type 2 diabetes living in high-income countries: a systematic review. *Acta Diabetol.* 54(8):785-794, 2017.
- 310.** Guglielmi V, Bellia A, Pecchioli S, Della-Morte D, Parretti D, Cricelli I, Medea G, Sbraccia P, Lauro D, Cricelli C, Lapi F. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. *Atherosclerosis.* 263:36-41, 2017.
- 311.** Bellia A, Iellamo F, De Carli E, Andreadi A, Padua E, Lombardo M, Annino G, Campoli F, Tartaglione S, D'Ottavio S, Della-Morte D, Lauro D. Exercise individualized by TRIMPI method reduces arterial stiffness in early onset type 2 diabetic patients: A randomized controlled trial with aerobic interval training. *Int J Cardiol.* 248:314-319, 2017.
- 312.** Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. *N Engl J Med.* 377(24):2337-2348, 2017.
- 313.** Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). *Diabetes Obes Metab.* 19(7):1024-1031, 2017.
- 314.** Strollo F, Gentile S. Comment on the New Indian Injection Technique Recommendations: Critical Appraisal of the Real-World Implementation of the Current Guidelines. *Diabetes Ther.* 8(3):507-511, 2017.
- 315.** Gentile S, Piscitelli P, Viazzi F, Russo G, Ceriello A, Giorda C, Guida P, Fioretto P, Pontremoli R, Strollo F, De Cosmo S; AMD-Annals Study Group. Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function. *Oncotarget.* 8(37):62039-62048, 2017.
- 316.** Maurizi AR, Menduni M, Del Toro R, Kyanvash S, Maggi D, Guglielmi C, Pantano AL, Defeudis G, Fioriti E, Manfrini S, Pozzilli P. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. *Acta Diabetol.* 54(4):361-365, 2017.
- 317.** Della Pepa G, Vetrani C, Lombardi G, Bozzetto L, Annuzzi G, Rivellese AA. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. *Nutrients.* 9(10), 2017.
- 318.** Dei Cas A, Spigoni V, Cito M, Aldigeri R, Ridolfi V, Marchesi E, Marina M, Derlindati E, Aloe R, Bonadonna RC, Zavaroni I. Vildagliptin, but not glibenclamide,

- increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. *Cardiovasc Diabetol.* 16(1):27, 2017.
- 319.** Policardo L, Seghieri G, Anichini R, Francesconi P. Effect of statins on hospitalization risk of bacterial infections in patients with or without diabetes. *Acta Diabetol.* 54(7):669-675, 2017.
- 320.** Monami M, Nreu B, Scatena A, Giannini S, Andreozzi F, Sesti G, Mannucci E. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. *J Endocrinol Invest.* 40(11):1251-1258, 2017.
- 321.** Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, Monami M. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. *Acta Diabetol.* 54(10):933-941, 2017.
- 322.** Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. *Diabetes Obes Metab.* 19(9):1233-1241, 2017.
- 323.** Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. *Endocrine.* 57(3):464-473, 2017.
- 324.** Monami M, Zannoni S, Pala L, Silverii A, Andreozzi F, Sesti G, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. *Int J Cardiol.* 1;240:414-421, 2017.
- 325.** Broglio F, Mannucci E, Napoli R, Nicolucci A, Purrello F, Nikonova E, Stager W, Trevisan R. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme. *Diabetes Obes Metab.* 19(2):248-256, 2017.
- 326.** Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. *Acta Diabetol.* 54(12):1101-1114, 2017. *Erratum in: Acta Diabetol.* 54(11):1069-1071, 2017.
- 327.** Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, Mezza T, Giaccari A. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. *Drug Des Devel Ther.* 11:2905-2919, 2017.

- 328.** Marfella R, Sardu C, Calabrò P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, Barbieri M. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment. *Diabetes Obes Metab.* 20(3):723-729, 2018.
- 329.** Chilelli NC, Bax G, Bonaldo G, Ragazzi E, Iafrate M, Zattoni F, Bellavere F, Lapolla A. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series. *Endocrine.* 59(3):690-693, 2018.
- 330.** Siegmund T, Tentolouris N, Knudsen ST, Lapolla A, Prager R, Phan TM, Wolden ML, Schultes B; EU-TREAT study group. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. *Diabetes Obes Metab.* 20(3):689-697, 2018.
- 331.** Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. *Diabetes Obes Metab.* 20(3):541-548, 2018.
- 332.** Vetrani C, Vitale M, Bozzetto L, Della Pepa G, Cocozza S, Costabile G, Mangione A, Cipriano P, Annuzzi G, Rivellese AA. Association between different dietary polyphenol subclasses and the improvement in cardiometabolic risk factors: evidence from a randomized controlled clinical trial. *Acta Diabetol.* 55(2):149-153, 2018.
- 333.** Fadini GP, Bottigliengo D, D'Angelo F, Cavalot F, Bossi AC, Zatti G, Baldi I, Avogaro A; DARWIN-T2D Network Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. *Diabetes Ther.* 9(4):1477-1490, 2018.
- 334.** Torre E, Bruno GM, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Parodi A, Bottaro LC, Colombo GL. Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. *Clinicoecon Outcomes Res.* 10:413-421, 2018.
- 335.** Spatola L, Finazzi S, Angelini C, Dauriz M, Badalamenti S. SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice. *Diabetes Ther.* 9(1):427-43, 2018.

- 336.** Sesti G, Antonelli Incalzi R, Bonora E, Consoli A, Giaccari A, Maggi S, Paolisso G, Purrello F, Vendemiale G, Ferrara N. Management of diabetes in older adults. *Nutr Metab Cardiovasc Dis.* 28(3):206-218, 2018.
- 337.** Venturini M, Marra P, Colarieti A, Agostini G, Lanza C, Augello L, Gusmini S, Salvioni M, Melissano G, Fiorina P, Chiesa R, De Cobelli F, Del Maschio A. Covered stenting and transcatheter embolization of splenic artery aneurysms in diabetic patients: A review of endovascular treatment of visceral artery aneurysms in the current era. *Pharmacol Res.* 135:127-135, 2018.
- 338.** Dellepiane S, Ben Nasr M, Assi E, Uselli V, Letizia T, D'Addio F, Zuccotti GV, Fiorina P. Sodium glucose cotransporters inhibitors in type 1 diabetes. *Pharmacol Res.* 133:1-8, 2018.
- 339.** Simioni N, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Lapolla A, Bette C, Rossi MC; ReaL (NN2211-4118) Study Group Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting. *Acta Diabetol.* 55(6):557-568, 2018.
- 340.** Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. *Adv Ther.* 35(2):243-253, 2018.
- 341.** Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A; DARWIN-T2D network. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. *Diabetes Obes Metab.* 20(7):1781-1786, 2018.
- 342.** Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Järvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. *Diabetes Obes Metab.* 20(3):541-548, 2018.
- 343.** Bertuzzi F, Stefani I, Rivolta B, Pintaudi B, Meneghini E, Luzi L, Mazzone A. Teleconsultation in type 1 diabetes mellitus (TELEDIABE). *Acta Diabetol.* 255(2):185-192, 2018.
- 344.** Pieralice S, Vigeveno F, Del Toro R, Napoli N, Maddaloni E. Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis. *Curr Diab Rep.* 18(10):84, 2018.
- 345.** Maddaloni E, Buzzetti R. Why only macro and not micro in type 2 diabetes? Time to change the goals of clinical trials in diabetes. *Diabetes Metab Res Rev.* 34(6):e3012 2018.

- 346.** Ballotari P, Venturelli F, Manicardi V, Ferrari F, Vicentini M, Greci M, Pignatti F, Storani S, Giorgi Rossi P. Effectiveness of integrated care model for type 2 diabetes: A population-based study in Reggio Emilia (Italy). *PLoS One*. 13(3):e0194784, 2018.
- 347.** Vicentini M, Ballotari P, Giorgi Rossi P, Venturelli F, Sacchettini C, Greci M, Mangone L, Pezzarossi A, Manicardi V. Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study. *Diabetes Res Clin Pract*. 143:398-408, 2018.
- 348.** Sardu C, Paolisso P, Sacra C, Santamaria M, de Lucia C, Ruocco A, Mauro C, Paolisso G, Rizzo MR, Barbieri M, Marfella R. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. *Cardiovasc Diabetol*. 17(1):137, 2018.
- 349.** Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabrò P, Mauro C, Pieretti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. *Diabetol Metab Syndr*. 10:1, 2018.
- 350.** Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G NAFLD/NASH in patients with type 2 diabetes and related treatment options. *J Endocrinol Invest*. 41(5):509-521, 2018.
- 351.** Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 392(10157):1519-1529, 2018.
- 352.** Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. *Diabetes Res Clin Pract*. 143:1-14, 2018.
- 353.** Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrech J, Martin S, Schloot NC. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials. *Diabetes Obes Metab*. 20(6):1490-1498, 2018.

- 354.** Scicali R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzo AM, Purrello F. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. *Acta Diabetol.* 55(3):209-218, 2018.
- 355.** Frison V, Simioni N, Marangoni A, Balzano S, Vinci C, Zenari L, De Moliner L, Tadiotto F, D'Ambrosio M, Confortin L, Marin N, Lombardi S, Costa S, Prosperini G, Lapolla A. Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study. *Diabetes Ther.* 9(6):2201-2208, 2018.
- 356.** Gentile S, Fusco A, Colarusso S, Piscopo M, Improta MR, Corigliano M, Martedi E, Oliva D, Santorelli A, Simonetti R, Giammarco A, Colella C, Miretto L, D'Alessandro A, Russo V, Guarino G, Marino G, Corigliano G, Strollo F. A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. *Expert Opin Drug Saf.* 17(5):445-450, 2018.
- 357.** Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G. Statins in liver disease: not only prevention of cardiovascular events. *Expert Rev Gastroenterol Hepatol.* 12(8):743-744, 2018.
- 358.** Pafili K, Rizzo M, Papanas N. New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. *Curr Opin Cardiol.* 33(4):444-454, 2018.
- 359.** Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of Statin Intolerance in 2018: Still More Questions Than Answers. *Am J Cardiovasc Drugs.* 18(3):157-173, 2018.
- 360.** Irace C, Casciaro F, Scavelli FB, Oliverio R, Cutruzzolà A, Cortese C, Gnasso A. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. *Cardiovasc Diabetol.* 17(1):52, 2018.
- 361.** Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. *Lancet Diabetes Endocrinol.* 6(1):27-40, 2018.

- 362.** Alsalim W, Göransson O, Carr RD, Bizzotto R, Tura A, Pacini G, Mari A, Ahrén B. Effect of single-dose DPP-4 inhibitor sitagliptin on β -cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects. *Diabetes Obes Metab.* 20(4):1080-1085, 2018.
- 363.** Visentin R, Schiavon M, Giegerich C, Klabunde T, Man CD, Cobelli C. Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator. *Conf Proc IEEE Eng Med Biol Soc.* 2018:4905-4908, 2018.
- 364.** Schiavon M, Dalla Man C, Cobelli C. Modeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes. *IEEE Trans Biomed Eng.* 65(9):2079-2086, 2018.
- 365.** Frias J, Puig Domingo M, Meneghini L, Napoli R, Liu M, Soltes Rak E, Aroda VR. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. *Diabetes Obes Metab.* S20(9):2314-2318, 2018.
- 366.** Kahleova H, Tura A, Hill M, Holubkov R, Barnard ND. A Plant-Based Dietary Intervention Improves Beta-Cell Function and Insulin Resistance in Overweight Adults: A 16-Week Randomized Clinical Trial. *Nutrients.* 10(2), 2018.
- 367.** Consoli A, Formoso G, Baldassarre MPA, Febo F. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. *Expert Opin Drug Saf.* 17(3):293-302, 2018.
- 368.** Gentile S, Guarino G, Martedì E, Della Corte T, Strollo F; Italian Study Group on Injection Techniques. Considerations on lipoatrophic skin lesions far from insulin injection sites. *Diabetes Res Clin Pract.* 40:347-350, 2018.
- 369.** Costabile G, Vitale M, Luongo D, Naviglio D, Vetrani C, Ciciola P, Tura A, Castello F, Mena P, Del Rio D, Capaldo B, Rivellese AA, Riccardi G, Giacco R. Grape pomace polyphenols improve insulin response to a standard meal in healthy individuals: A pilot study. *Clin Nutr.* 38 (6):272-2734,2019.
- 370.** Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. *Diabetes Obes Metab.* 21:903-908, 2019.
- 371.** Kahleova H, Tura A, Klementova M, Thieme L, Haluzik M, Pavlovicova R, Hill M, Pelikanova T. A Plant-Based Meal Stimulates Incretin and Insulin Secretion More Than an Energy- and Macronutrient-Matched Standard Meal in Type 2 Diabetes: A Randomized Crossover Study. *Nutrients,* 11(3):pii:E486, 2019.

- 372.** Karusheva Y, Koessler T, Strassburger K, Markgraf D, Mastrototaro L, Jelenik T, Simon MC, Pesta D, Zaharia OP, Bódis K, Bärenz F, Schmoll D, Wolkersdorfer M, Tura A, Pacini G, Burkart V, Müssig K, Szendroedi J, Roden M. Short-term dietary reduction of branched-chain amino acids reduces meal-induced insulin secretion and modifies microbiome composition in type 2 diabetes: a randomized controlled crossover trial. *Am J Clin Nutr*, 110(5):1098-1107, 2019.
- 373.** Sardu C, Paolisso P, Sacra C, Mauro C, Minicucci F, Portoghese M, Rizzo MR, Barbieri M, Sasso FC, D'Onofrio N, Balestrieri ML, Calabrò P, Paolisso G, Marfella R. Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients With Prediabetes With Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. *Diabetes Care*, 42:1946-1955, 2019
- 374.** Urbano F, Di Pino A, Scicali R, Filippello A, Di Mauro S, Scamporrino A, Marchisello S, Rabuazzo AM, Purrello F, Piro S. Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. *Eur J. Endocrinol*, 181:579-590, 2019.
- 375.** Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A; TOSCA.IT Investigators. Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. *J Clin Endocrinol Metab*, 104(8):3296-3302, 2019.
- 376.** Maggi D, Montecucco F, Adami G, Cordera R. Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently). *Diabetol Metab Syndr*, 11:48, 2019
- 377.** Gentilella R, Sesti G, Vazquez L, Sapin H, Reed V, Romera I, Pozzilli P. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. *Diabetes Obes Metab*, 21(12):2660-2666, 2019.
- 378.** Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. *Diabetes Obes Metab*, 21(2):252-260, 2019.
- 379.** Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Örsy P, Sabbah M, Sesti G, Silver R. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a

- multicentre, open-label, phase 3b, randomised controlled trial. *Lancet Diabetes Endocrinol*, 7(8):596-605, 2019.
380. Fadini GP, Sarangdhar M, De Ponti F, Avogaro A, Raschi E. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. *BMJ Open Diabetes Res Care*, 7(1):e000725, 2019
 381. Esposti LD, Perrone V, Saragoni S, Blini V, Buda S, D'avella R, Gasperini G, Lena F, Fanelli F, Gazzi L, Giorgino F. Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. *J Diabetes Res*, 2019:3174654, 2019.
 382. Gentilella R, Romera I, Nicolay C, Buzzetti R, Vázquez LA, Sesti G. Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents. *Diabetes Ther*, 10(3):1113-1125, 2019.
 383. Geagea AG, Rizzo M, Jurjus A, Cappello F, Leone A, Tomasello G, Gracia C, Kattar SA, Massaad-Massade L, Eid A. Correction: A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. *Oncotarget*, 10(60):6538-6539, 2019.
 384. Castellino G, Nikolic D, Magán-Fernández A, Malfa GA, Chianetta R, Patti AM, Amato A, Montalto G, Toth PP, Banach M, Cicero AFG, Rizzo M. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients*, 11(11): pii:E2580, 2019.
 385. Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, Citarrella R, Corrado E, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. *Diabetes Res. Clin. Pract*, 149:163-169, 2019.
 386. Cianflone D, Rizvi AA, Rizzo M. Microvascular and macrovascular effects of liraglutide. *Int. J. Cardiol*, 286:17-18, 2019.
 387. Bain SC, Mosenzon O, Arechavaleta R, Bogdański P, Comlekci A, Consoli A, Deerochanawong C, Dungan K, Faingold MC, Farkouh ME, Franco DR, Gram J, Guja C, Joshi P, Malek R, Merino-Torres JF, Nauck MA, Pedersen SD, Sheu WH, Silver RJ, Tack CJ, Tandon N, Jeppesen OK, Strange M, Thomsen M, Husain M. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. *Diabetes Obes Metab*, 21(3):499-508, 2019.

- 388.** Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP). Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res*, 143:1-16, 2019.
- 389.** Fogacci F, Cicero AFG, Derosa G, Rizzo M, Veronesi M, Borghi C. Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. *Crit Rev Food Sci Nutr*, 59(2):328-335, 2019.
- 390.** Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. *Diabetologia*, 62(6):948-958, 2019.
- 391.** Fadini GP, Frison V, Simioni N, Lapolla A, Gatti A, Bossi AC, Del Buono A, Fornengo P, Gottardo L, Laudato M, Perseghin G, Bonora E, Avogaro A. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. *J Am Heart Assoc*, 8(14):e012244, 2019.
- 392.** Bonadonna RC, Giaccari A, Buzzetti R, Aimaretti G, Cucinotta D, Avogaro A, Perseghin G, Larosa M, Bolli GB, Fanelli CG. Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population. *Nutr Metab Cardiovasc Dis*, 29(5):496-503, 2019.
- 393.** Bolla AM, Caretto A, Laurenzi A, Scavini M, Piemonti L. Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes. *Nutrients*, 11(5):pii:E962, 2019.
- 394.** Polito R, Costabile G, Nigro E, Giacco R, Vetrani C, Anniballi G, Luongo D, Riccardi G, Daniele A, Annuzzi G. Nutritional factors influencing plasma adiponectin levels: results from a randomised controlled study with whole-grain cereals. *Int J Food Sci Nutr*, 1-7, 2019.
- 395.** Bozzetto L, Alderisio A, Clemente G, Giorgini M, Barone F, Griffo E, Costabile G, Vetrani C, Cipriano P, Giacco A, Riccardi G, Rivellese AA, Annuzzi G. Gastrointestinal effects of extra-virgin olive oil associated with lower postprandial glycemia in type 1 diabetes. *Clin Nutr*, 38(6):2645-2651, 2019.
- 396.** Vetrani C, Bozzetto L, Giorgini M, Cavagnuolo L, Di Mattia E, Cipriano P, Mangione A, Todisco A, Inghilterra G, Giacco A, Annuzzi G, Rivellese AA. Fibre-enriched

- buckwheat pasta modifies blood glucose response compared to corn pasta in individuals with type 1 diabetes and celiac disease: Acute randomized controlled trial. *Diabetes Res Clin Pract*, 149:156-162, 2019.
- 397.** Cavagnuolo L, Bozzetto L, Franco L, Costabile G, Riccardi G, Rivellese AA, Annuzzi G. Pizza Leavening Technique Influences Postprandial Glucose Response: A Randomized Controlled Trial in Patients With Type 1 Diabetes. *Diabetes Care*, 42(10):e157-e158, 2019.
- 398.** Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C, Orsi E, Picconi F, Resi V, Bonora E, Purrello F. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. *Acta Diabetol*, 56(6):605-617, 2019.
- 399.** Bonora BM, Vigili de Kreutzenberg S, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. *Cardiovasc Diabetol*, 18(1): 106, 2019.
- 400.** Bonora BM, Avogaro A, Fadini GP. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Acta Diabetol*, 56(9):1051-1060, 2019.
- 401.** Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchiolla P, Arena S, Buzzetti R, Avogaro A; DARWIN-T2D network. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. *Diabetes Obes Metab*, 21(8):1886-1894, 2019.
- 402.** Morieri ML, Rigato M, Frison V, Simioni N, D'Ambrosio M, Tadiotto F, Paccagnella A, Lapolla A, Avogaro A, Fadini GP. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. *Diabetes Obes Metab*, 21(11):2542-2552, 2019.
- 403.** Fadini GP, Bonora BM, Lapolla A, Fattor B, Morpurgo PS, Simioni N, Avogaro A; DARWIN-T2D Network. Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies. *Diabetes Obes Metab*, 21(5):1255-1260, 2019.
- 404.** Vitale M, Masulli M, Rivellese AA, Bonora E, Babini AC, Sartore G, Corsi L, Buzzetti R, Citro G, Baldassarre MPA, Bossi AC, Giordano C, Auciello S, Dall'Aglio E, Iannarelli R, Tonutti L, Sacco M, Di Cianni G, Clemente G, Gregori G, Grioni S, Krogh V,

- Riccardi G, Vaccaro O. Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes-TOSCA.IT Study. *Nutrients*, 12(1):101, 2019.
405. Mirabelli M, Chiefari E, Caroleo P, Vero R, Brunetti FS, Corigliano DM, Arcidiacono B, Foti DP, Puccio L, Brunetti A. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus. *J Diabetes Res*, 2019:3971060, 2019.
 406. Canello R, Turrone S, Rampelli S, Cattaldo S, Candela M, Cattani L, Mai S, Vietti R, Scacchi M, Brigidi P, Invitti C. Effect of Short-Term Dietary Intervention and Probiotic Mix Supplementation on the Gut Microbiota of Elderly Obese Women. *Nutrients*, 11(12):3011, 2019.
 407. Carnovale C, Pozzi M, Dassano A, D'Addio F, Gentili M, Magni C, Clementi E, Radice S, Fiorina P. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis. *Acta Diabetol*, 56(3):341-354, 2019.
 408. Tentolouris N, Knudsen ST, Lapolla A, Wolden ML, Haldrup S, Schultes B. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control. *Adv. Ther*, 36:1201-1210, 2019.
 409. D'Aronco S, Crotti S, Agostini M, Traldi P, Chilelli NC, Lapolla A. The role of mass spectrometry in studies of glycation processes and diabetes management. *Mass Spectrom Rev*, 38(1):112-146, 2019.
 410. Corrao G, Monzio Compagnoni M, Ronco R, Merlino L, Ciardullo S, Perseghin G, Banfi G. Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? *Clin. Orthop. Relat. Res*, doi: 10.1097/CORR.0000000000001089, 2019
 411. Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, Mariani S, Lubrano C, Poggiogalle E, Migliaccio S, Donini LM, Basciani S, Cignarelli A, Conte E, Ceccarini G, Bogazzi F, Cimino L, Condorelli RA, La Vignera S, Calogero AE, Gambineri A, Vignozzi L, Prodam F, Aimaretti G, Linsalata G, Buralli S, Monzani F, Aversa A, Vettor R, Santini F, Vitti P, Gnassi L, Pagotto U, Giorgino F, Colao A, Lenzi A; Cardiovascular Endocrinology Club of the Italian Society of Endocrinology. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus

- statement from the Italian Society of Endocrinology (SIE). *J Endocrinol Invest*, 42(11):1365-1386, 2019.
412. Sartore G, Chilelli NC, Seraglia R, Ragazzi E, Marin R, Roverso M, Cosma C, Vaccaro O, Burlina S, Lapolla A. Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. *Acta Diabetol*, 56(5):505-513, 2019.
413. Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis. *Diabetes Metab Res Rev*, 35(1):e3082, 2019.
414. Caruso I, Cignarelli A, Giorgino F. Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. *Trends Endocrinol Metab*, 30(9):578-589, 2019.
415. Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, Giorgino F. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. *Sci Rep*, 9(1):19351, 2019.
416. Basu R, Schiavon M, Petterson XM, Hinshaw L, Slama M, Carter R, Man CD, Cobelli C, Basu A. A novel natural tracer method to measure complex carbohydrate metabolism. *Am J Physiol Endocrinol Metab*, 317(3):E483-E493, 2019.
417. Visentin R, Schiavon M, Giegerich C, Klabunde T, Man CD, Cobelli C. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies. *IEEE Trans Biomed Eng*, 66(10):2889-2896, 2019.
418. D'Alessandro A, Lampignano L, De Pergola G. Mediterranean Diet Pyramid: A Proposal for Italian People. A Systematic Review of Prospective Studies to Derive Serving Sizes. *Nutrients*, 11(6):1296, 2019.
419. Fadini GP, Feher M, Hansen TK, de Valk HW, Koefoed MM, Wolden M, Zimmermann E, Jendle J. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. *J Clin Endocrinol Metab*, 104(12):5977-5990, 2019.
420. Brede S, Fehr S, Dalla-Man C, Cobelli C, Lehnert H, Hallschmid M, Klement J. Intranasal oxytocin fails to acutely improve glucose metabolism in obese men. *Diabetes Obes Metab*, 21(2):424-428, 2019.

421. Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice. *Adv. Ther*, 36:2895-2909, 2019.
422. Salvatore T, Pafundi PC, Marfella R, Sardu C, Rinaldi L, Monaco L, Riconzi C, Imbriani S, Nevola R, Adinolfi LE, Sasso FC. Metformin lactic acidosis: Should we still be afraid? *Diabetes Res. Clin. Pract*, 157:107879, 2019.
423. Cavallari I, Maddaloni E. Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand. *Diabetes Metab. Res. Rev*, 35:e3124, 2019.
424. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. *Nat. Rev. Cardiol*, 16:113-130, 2019.
425. Dassano A, Loretelli C, Fiorina P. Idebenone and T2D: A new insulin-sensitizing drug for personalized therapy. *Pharmacol Res*, 139:469-470, 2019.
426. Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. *Cardiovasc Diabetol*, 18(1):20, 2019.
427. Giaccari A. Sodium-glucose co-transporter inhibitors: Medications that mimic fasting for cardiovascular prevention. *Diabetes Obes Metab*, 21(10):2211-2218, 2019.
428. Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. *J Diabetes Complications*, 33(3):236-242, 2019.
429. Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial. *Diabetes Obes Metab*, 21(11):2570-2575, 2019.
430. Della Pepa G, Vetrani C, Brancato V, Vitale M, Monti S, Annuzzi G, Lombardi G, Izzo A, Tommasone M, Cipriano P, Clemente G, Mirabelli P, Mancini M, Salvatore M, Riccardi G, Rivellese AA, Bozzetto L. Effects of a multifactorial ecosustainable isocaloric

- diet on liver fat in patients with type 2 diabetes: randomized clinical trial. *BMJ Open Diabetes Res Care*. 8(1):e001342, 2020.
- 431.** Vetrani C, Maukonen J, Bozzetto L, Della Pepa G, Vitale M, Costabile G, Riccardi G, Rivellese AA, Saarela M, Annuzzi G. Diets naturally rich in polyphenols and/or long-chain n-3 polyunsaturated fatty acids differently affect microbiota composition in high-cardiometabolic-risk individuals. *Acta Diabetol*. 57(7):853-860, 2020.
- 432.** Polito R, Costabile G, Nigro E, Giacco R, Vetrani C, Anniballi G, Luongo D, Riccardi G, Daniele A, Annuzzi G. Nutritional factors influencing plasma adiponectin levels: results from a randomised controlled study with whole-grain cereals. *Int J Food Sci Nutr*. 71(4):509-515, 2020.
- 433.** Morieri ML, Avogaro A, Fadini GP. Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. *Diabetes Metab Syndr Obes*. 13:4221-4234, 2020.
- 434.** Morieri ML, Fadini GP, Boscari F, Fioretto P, Maran A, Busetto L, Crepaldi MC, Vedovato M, Bonora BM, Selmin E, Arcidiacono G, Pinelli S, Farnia F, Falaguasta D, Russo L, Voltan G, Mazzocut S, Costantini G, Ghirardini F, Tresso S, Cattelan AM, Vianello A, Vettor R, Avogaro A. Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19. *Diabetes Res Clin Pract*. 168:108449, 2020.
- 435.** Peng XV, McCrimmon RJ, Shepherd L, Boss A, Lubwama R, Dex T, Skolnik N, Ji L, Avogaro A, Blonde L. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. *Diabetes Ther*. 11(11):2629-2645, 2020.
- 436.** Morieri ML, Bonora BM, Longato E, Di Camilo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis. *Diabetes Obes Metab*. 22(10):1925-1934, 2020.
- 437.** Longato E, Di Camillo B, Sparacino G, Gubian L, Avogaro A, Fadini GP. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. *BMJ Open Diabetes Res Care*. 8(1):e001451, 2020.
- 438.** Mazzucato M, Fioretto P, Avogaro A. High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors? *Diabetes Obes Metab*. 22(9):1511-1515, 2020.
- 439.** Avogaro A, Fadini GP. Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss? *Lancet Diabetes Endocrinol*. 8(5):353-355, 2020.

440. Morieri ML, Frison V, Rigato M, D'Ambrosio M, Tadiotto F, Paccagnella A, Simioni N, Lapolla A, Avogaro A, Fadini GP. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. *J Clin Endocrinol Metab.* 105(7):dgaa204, 2020.
441. Rigato M, Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. *J Clin Endocrinol Metab.* 105(7):dgaa178, 2020.
442. Morieri ML, Rigato M, Frison V, Simioni N, D'Ambrosio M, Tadiotto F, Paccagnella A, Lapolla A, Avogaro A, Fadini GP. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. *Metabolism.* 106:154190, 2020.
443. Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. *Diabetes Metab Syndr Obes.* 13:161-174, 2020.
444. Sciannameo V, Berchialla P, Orsi E, Lamacchia O, Morano S, Querci F, Consoli A, Avogaro A, Fadini GP; DARWIN-T2D study. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. *Diabetes Obes Metab.* 22(5):817-827, 2020.
445. Fadini GP, Frison V, Rigato M, Morieri ML, Simioni N, Tadiotto F, D'Ambrosio M, Paccagnella A, Lapolla A, Avogaro A. Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. *Acta Diabetol* 57(3):367-375, 2020.
446. Fadini GP, Li Volsi P, Devangelio E, Poli M, Cazzetta G, Felace G, Avogaro A; DARWIN-T2D Network. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. *J Endocrinol Invest.* 43(3):329-336, 2020.
447. Rinaldi E, Zenti MG, Trombetta M, Ceradini G, Altomari A, Boselli ML, Santi L, Battistoni M, Bonadonna RC, Bonora E. Changes induced by metabolic surgery on the main components of glucose/insulin system in patients with diabetes and obesity. *Acta Diabetol.* [Epub ahead of print], 2020.
448. Freemantle N, Bonadonna RC, Gourdy P, Mauricio D, Mueller-Wieland D, Bigot G, Ciocca A, Mauquoi C, Rollot M, Bonnemaire M. Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project. *BMJ Open.* 10(4):e033659, 2020.

- 449.** Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis. *Int J Environ Res Public Health*. 17(10):3664, 2020.
- 450.** Orsi E, Bonora E, Solini A, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Zerbini G, Morano S, Nicolucci A, Penno G, Pugliese G. Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. *J Clin Med*. 17;9(1):246, 2020.
- 451.** Derosa G, D'Angelo A, Martinotti C, Valentino MC, Di Matteo S, Bruno GM, Maffioli P. Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. *Int J Vitam Nutr Res*. 14:1-10, 2020.
- 452.** Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL. Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. *Clinicoecon Outcomes Res*. 12:177-189, 2020.
- 453.** Lombardo M, Bellia C, Moletto C, Aulisa G, Padua E, Della-Morte D, Caprio M, Bellia A. Effects of Quality and Quantity of Protein Intake for Type 2 Diabetes Mellitus Prevention and Metabolic Control. *Curr Nutr Rep*. 9(4):329-337, 2020.
- 454.** Caprio M, Vitale C, Rosano GMC. From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents. *Eur Heart J Cardiovasc Pharmacother*. pvaa019, 2020.
- 455.** Moriconi E, Feraco A, Marzolla V, Infante M, Lombardo M, Fabbri A, Caprio M. Neuroendocrine and Metabolic Effects of Low-Calorie and Non-Calorie Sweeteners. *Front Endocrinol (Lausanne)*. 11:444, 2020.
- 456.** Cordera R, Pinducciu C, Maggi D. Type 1 diabetes and technology at time of COVID-19: A case report. *Eur J Clin Invest*. e13290, 2020.
- 457.** Irace C, Cutruzzolà A, Nuzzi A, Assaloni R, Brunato B, Pitocco D, Tartaglione L, Di Molfetta S, Cignarelli A, Laviola L, Citro G, Lovati E, Gnasso A, Tweden KS, Kaufman FR. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. *Diabetes Obes Metab*. 22(7):1056-1061, 2020.
- 458.** Castellana M, Parisi C, Di Molfetta S, Di Gioia L, Natalicchio A, Perrini S, Cignarelli A, Laviola L, Giorgino F. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open Diabetes Res Care*. 8(1):e001092, 2020.

- 459.** Caruso I, Cignarelli A, Natalicchio A, Perrini S, Laviola L, Giorgino F. Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection. *Metabolism*. 109:154272, 2020.
- 460.** Caruso I, Di Molfetta S, Guarini F, Giordano F, Cignarelli A, Natalicchio A, Perrini S, Leonardini A, Giorgino F, Laviola L. Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown following SARS-CoV-2 outbreak in type 1 diabetes. *Diabetes Metab Res Rev*. 11:e3404, 2020.
- 461.** Schiavon M, Visentin R, Giegerich C, Sieber J, Dalla Man C, Cobelli C, Klabunde T. In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes. *Diabetes Technol Ther*. 22(8):553-561, 2020.
- 462.** Toffanin C, Kozak M, Sumnik Z, Cobelli C, Petruzelkova L. In Silico Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. *Diabetes Technol Ther*. 22(2):112-120, 2020.
- 463.** Bynoe K, Unwin N, Taylor C, Murphy MM, Bartholomew L, Greenidge A, Abed M, Jeyaseelan S, Cobelli C, Dalla Man C, Taylor R. Inducing remission of Type 2 diabetes in the Caribbean: findings from a mixed methods feasibility study of a low-calorie liquid diet-based intervention in Barbados. *Diabet Med*. 37(11):1816-1824, 2020.
- 464.** Schiavon M, Visentin R, Giegerich C, Klabunde T, Cobelli C, Dalla Man C. Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes. *IEEE Trans Biomed Eng*. 67(2):624-631, 2020.
- 465.** Di Dalmazi G, Coluzzi S, Baldassarre MPA, Sorbo SE, Dell'Aquila S, Febo F, Ginestra F, Graziano G, Rossi MC, Consoli A, Formoso G. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. *Clin Ther*. 42(9):1738-1749.e1, 2020.
- 466.** Consoli A, Czupryniak L, Duarte R, Jermendy G, Kautzky-Willer A, Mathieu C, Melo M, Mosenzon O, Nobels F, Papanas N, Roman G, Schnell O, Sotiropoulos A, Stehouwer CDA, Tack CJ, Woo V, Fadini GP, Raz I. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. *Diabetes Obes Metab*. 22(10):1705-1713, 2020.
- 467.** Vadini F, Simeone PG, Boccata A, Guagnano MT, Liani R, Tripaldi R, Di Castelnovo A, Cipollone F, Consoli A, Santilli F. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. *Int J Obes (Lond)*. 44(6):1254-1263, 2020.

468. Sciannimanico S, Grimaldi F, Vescini F, De Pergola G, Iacoviello M, Licchelli B, Guastamacchia E, Giagulli VA, Triggiani V. Metformin: Up to Date. *Endocr Metab Immune Disord Drug Targets*. 20(2):172-181, 2020.
469. Albiero M, Bonora BM, Fadini GP. Diabetes pharmacotherapy and circulating stem/progenitor cells. State of the art and evidence gaps. *Curr Opin Pharmacol*. 55:151-156, 2020.
470. Raschi E, Fadini GP, Diemberger I, Poluzzi E, De Ponti F. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? *Expert Opin Pharmacother*. 13:1-4, 2020.
471. Fadini GP, Giordano C, Salvi L, Nicolucci A; REFLECT Italian Study Group. Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study. *Diabetes Ther*. 11(12):2909-2920, 2020.
472. de Valk HW, Feher M, Hansen TK, Jendle J, Koefoed MM, Rizi EP, Zimmermann E, Fadini GP. Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study. *Diabetes Ther*. 11(9):2159-2167, 2020.
473. Fadini GP. SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes. *Cell Metab*. 5;31(5):883, 2020.
474. Fadini GP, Tentolouris N, Caballero Mateos I, Bellido Castañeda V, Morales Portillo C. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe. *Diabetes Ther*. 11(2):423-436, 2020.
475. Solerte SB, D'Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, Dell'Acqua M, Ippolito E, Scaranna C, Bellante R, Galliani S, Dodesini AR, Lepore G, Geni F, Fiorina RM, Catena E, Corsico A, Colombo R, Mirani M, De Riva C, Oleandri SE, Abdi R, Bonventre JV, Rusconi S, Folli F, Di Sabatino A, Zuccotti G, Galli M, Fiorina P. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. *Diabetes Care*. 43(12):2999-3006, 2020.
476. Berra C, Manfrini R, Regazzoli D, Radaelli MG, Disoteo O, Sommesse C, Fiorina P, Ambrosio G, Folli F. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. *Pharmacol Res*. 160:105052, 2020.

477. Berra CC, Resi V, Mirani M, Folini L, Rossi A, Solerte SB, Fiorina P. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. *Pharmacol Res.* 159:104996, 2020.
478. Rodbard HW, Giaccari A, Lajara R, Stewart J, Strumph PS, Oliveira J, Lapuerta P, Castro R. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2. *Diabetes Obes Metab.* 22(11):2089-2096, 2020.
479. Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyễn-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. *Curr Med Res Opin.* 36(4):571-581, 2020.
480. Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. *Diabetes Res Clin Pract.* 172:108617, 2020.
481. Giorgino F, Vora J, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. *Cardiovasc Diabetol.* 19(1):196, 2020.
482. Giorgino F, Caruso I, Napoli R. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 170:108478, 2020.
483. Boye KS, Sapin H, García-Pérez LE, Rosilio M, Orsini Federici M, Heitmann E, Jung H, Aigner U, Guerci B, Giorgino F, Norrbacka K. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes. *Diabetes Ther.* 11(10):2383-2399, 2020.
484. Morea N, Retnakaran R, Vidal J, Aroda VR, Liu M, Saremi A, Giorgino F. iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study. *Diabetes Obes Metab.* 22(9):1683-1689, 2020.

- 485.** Giorgino F, Vora J, Fenici P, Solini A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients? *Diabetes Obes Metab.* 22(9):1481-149, 2020.
- 486.** Khunti K, Giorgino F, Berard L, Mauricio D, Harris SB. The importance of the initial period of basal insulin titration in people with diabetes. *Diabetes Obes Metab.* 22(5):722-733, 2020.
- 487.** Lapolla A, Genovese S, Giorgino F, Disoteo O, Sartore G, Bartezaghi M, Del Prato S. Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. *Curr Med Res Opin.* 36(4):555-562, 2020.
- 488.** Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. *Diabetes Obes Metab.* 22(3):346-354, 2020.
- 489.** Giorgino F, Caruso I, Moellmann J, Lehrke M. Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. *Metabolism.* 104:154045, 2020.
- 490.** Davidson JA, Desouza C, Fonseca V, Frias JP, Van Gaal L, Giorgino F, Chao J, Dex TA, Roberts M, Saremi A, Leiter LA. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. *Diabet Med.* 37(2):256-266, 2020.
- 491.** Irace C, Cutruzzolà A, Parise M, Fiorentino R, Frazzetto M, Gnasso C, Casciaro F, Gnasso A. Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study. *Diab Vasc Dis Res.* 17(1):1479164119883540, 2020.
- 492.** Menini S, Iacobini C, Fantauzzi CB, Pugliese G. L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes. *Curr Med Chem.* 27(11):1744-1763, 2020.
- 493.** Lapolla A, Dalfrà MG. Hundred Years of Insulin Therapy: Purified Early Insulins. *Am J Ther.* 27(1):e24-e29, 2020.
- 494.** Haldrup S, Lapolla A, Gundgaard J, Wolden ML. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. *J Med Econ.* 23(3):271-279, 2020.

- 495.** Salvatore T, Pafundi PC, Morgillo F, Di Liello R, Galiero R, Nevola R, Marfella R, Monaco L, Rinaldi L, Adinolfi LE, Sasso FC. Metformin: An old drug against old age and associated morbidities. *Diabetes Res Clin Pract.* 160:108025, 2020.
- 496.** Sinclair AJ, Dunning T, Dhatariya K; an International Group of Experts. Clinical guidelines for type 1 diabetes mellitus with an emphasis on older adults: an Executive Summary. *Diabet Med.* 37(1):53-70, 2020.
- 497.** Maddaloni E, Coraggio L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R. Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy. *Diabetes Care.* 43(8):e86-e87, 2020.
- 498.** Margonato D, Galati G, Mazzetti S, Cannistraci R, Perseghin G, Margonato A, Mortara A. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. *Heart Fail Rev.* [Epub ahead of print], 2020.
- 499.** Corrao G, Monzio Compagnoni M, Ronco R, Merlino L, Ciardullo S, Perseghin G, Banfi G. Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? *Clin Orthop Relat Res.* 478(5):992-1003, 2020.
- 500.** Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, Leslie RD. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. *Diabetes.* 69(10):2037-2047, 2000.
- 501.** Pozzilli P, Bosi E, Cirkel D, Harris J, Leech N, Tinahones FJ, Vantyghem MC, Vlasakakis G, Ziegler AG, Janmohamed S. Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. *J Clin Endocrinol Metab.* 105(6):dgaa149, 2020.
- 502.** Di Mauro A, Tuccinardi D, Watanabe M, Del Toro R, Monte L, Giorgino R, Rampa L, Rossini G, Kyanvash S, Soare A, Rosati M, Piccoli A, Napoli N, Fioriti E, Pozzilli P, Khazrai YM, Manfrini S. The Mediterranean diet increases glucagon-like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross-over trial. *Diabetes Metab Res Rev.* 14:e3406, 2020.
- 503.** Forst T, Choudhary P, Schneider D, Linetzky B, Pozzilli P. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. *Diabetes Metab Res Rev.* 23:e3418, 2020.
- 504.** Giglio RV, Carruba G, Cicero AFG, Banach M, Patti AM, Nikolic D, Cocciadiferro L, Zarcone M, Montalto G, Stoian AP, Banerjee Y, Rizvi AA, Toth PP, Rizzo M. Pasta Supplemented with *Opuntia ficus-indica* Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors

- for the Metabolic Syndrome: A Four-Week Intervention Study. *Metabolites*. 10(11):42, 2020.
- 505.** Patti AM, Carruba G, Cicero AFG, Banach M, Nikolic D, Giglio RV, Terranova A, Soresi M, Giannitrapani L, Montalto G, Stoian AP, Banerjee Y, Rizvi AA, Toth PP, Rizzo M. Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. *Metabolites*. 10(10):392, 2020.
 - 506.** Sachinidis A, Nikolic D, Stoian AP, Papanas N, Tarar O, Rizvi AA, Rizzo M. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. *Metabolism*. 111:154343, 2020.
 - 507.** Stoian AP, Papanas N, Prazny M, Rizvi AA, Rizzo M. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. *J Cardiovasc Pharmacol Ther*. 25(6):494-496, 2020.
 - 508.** Ceriello A, Stoian AP, Rizzo M. COVID-19 and diabetes management: What should be considered? *Diabetes Res Clin Pract*. 163:108151, 2020.
 - 509.** Stoian AP, Banerjee Y, Rizvi AA, Rizzo M. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. *Metab Syndr Relat Disord*. 18(4):173-17, 2020.
 - 510.** Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. *Metabolites*. 11(1):22, 2020.
 - 511.** Lippi G, Targher G. Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy. *Clin Chem Lab Med*. 2020 Jul 28;58(8):e144-e147
 - 512.** Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. *Diabetes Metab*. 46(6):427-441, 2020.
 - 513.** Targher G, Byrne CD. Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. *Eur Heart J*. 41(2):331, 2020.
 - 514.** Mari A, Tura A, Grespan E, Bizzotto R. Mathematical Modeling for the Physiological and Clinical Investigation of Glucose Homeostasis and Diabetes. *Front Physiol*. 11:575789, 2020.

- 515.** Kahleova H, Petersen KF, Shulman GI, Alwarith J, Rembert E, Tura A, Hill M, Holubkov R, Barnard ND. Effect of a Low-Fat Vegan Diet on Body Weight, Insulin Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid Levels in Overweight Adults: A Randomized Clinical Trial. *JAMA Netw Open*. 3(11):e2025454, 2020.
- 516.** Kahleova H, Rembert E, Alwarith J, Yonas WN, Tura A, Holubkov R, Agnello M, Chutkan R, Barnard ND. Effects of a Low-Fat Vegan Diet on Gut Microbiota in Overweight Individuals and Relationships with Body Weight, Body Composition, and Insulin Sensitivity. A Randomized Clinical Trial. *Nutrients*. 12(10):2917, 2020.
- 517.** Alsalim W, Göransson O, Tura A, Pacini G, Mari A, Åhrén B. Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. *Diabetes Obes Metab*. 22(4):590-598, 2020.
- 518.** Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV, Ceriello A, Rhee M, Phillips LS, Chung S, Cravalho C, Jagannathan R, Monnier L, Colette C, Owens D, Bianchi C, Del Prato S, Monteiro MP, Neves JS, Medina JL, Macedo MP, Ribeiro RT, Filipe Raposo J, Dorcely B, Ibrahim N, Buysschaert M. Review of methods for detecting glycemic disorders. *Diabetes Res Clin Pract*. 165:108233, 2020.
- 519.** Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, Monami M. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis*. 30(7):1106-1114, 2020.
- 520.** Lane WS, Favaro E, Rathor N, Jang HC, Kjærsgaard MIS, Oviedo A, Rose L, Senior P, Sesti G, Soto Gonzalez A, Franek E. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). *Diabetes Care*. 43(8):1710-1716, 2020.
- 521.** Monami M, Naletto L, Nreu B, Dicembrini I, Sesti G, Mannucci E. Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract*. 162:108115, 2020.
- 522.** Sesti G, Bardtrum L, Dagdelen S, Halladin N, Haluzík M, Orsy P, Rodríguez M, Aroda VR. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. *Diabetes Obes Metab*. 22(5):873-878, 2020.